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Description: A technique developed
in 2007 and adapted here in chalk,
“Brainbow” maps individual neurons
simultaneously with fluorescent
proteins. This method randomly expresses different ratios of red, green
and blue derivatives, allowing for
more than 100 different neurons and
their connections to be illuminated.
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editorial

Mysteries of the brain and mind

“

If it seems to neurologists that our present understanding of
the brain and the mind of man is hardly more than a beginning of
science it may be reassuring to recall that our task is the ultimate
one. The problem of neurology is to understand man himself.
— Dr. Wilder Penfield, 19651

The human brain, at approximately three pounds with an estimated 86 billion neurons,2 is the most complex organ in the human
body and arguably, the most complex structure in the known universe. It controls all processes in the body, from autonomic functions that maintain life, such as heart rate and respiratory rate, to
the ability to perceive and act on our environment. The brain is responsible for our emotions and thoughts, and enables us to learn,
innovate, and create. It shapes our awareness of time and space, and
of others and ourselves, and ultimately makes us human. Unsurprisingly, disorders of the brain can be deadly or severely debilitating for patients, their families, and society.
Although our current understanding of the human brain and
mind is indeed “hardly more than a beginning of science,” technological developments over the past fifty years have enabled many
problems in neuroscience to be approached. For example, advances
in functional genomics and the ability to sequence the entire human
genome have enabled scientists to characterize neuronal diversity
at the molecular level, identify genes that contribute to disease, and
examine fundamental principles of neurobiology.3 Optogenetics has
provided neuroscientists with a tool for manipulating specific neuronal activity to study the neural circuits that underlie behavior.4
With regard to investigating human brain function and dysfunction,
functional magnetic resonance imaging (fMRI) has undoubtedly
become the method of choice due to its noninvasive nature, relatively high spatial resolution, and ability to image the whole brain.5
Supported by basic science, clinical neuroscience seeks to improve our understanding of disease processes and guide prevention, diagnosis, and treatment. Notably, insights into the neural basis of cognition, emotion, and social behaviour have the potential
to transform how psychiatric disorders are diagnosed and treated.
Accordingly, the U.S. National Institute of Mental Health launched
the Research Domain Criteria project five years ago to help reframe
mental disorders as brain disorders based on genetics, neural circuits, behaviour, and symptoms.6 Knowledge of brain function can
also be translated into effective interventions. As an example, deep
brain stimulation has become an established therapy for the management of Parkinson’s disease, tremor, and dystonia, and is being
investigated for the treatment of psychiatric disorders such as obsessive-compulsive disorder and treatment-resistant depression.7
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Beyond the scientific and medical community, brain research has received considerable attention from politicians,
governments, and the general public. In 2013, two major brain
research projects — the European Commission’s Human Brain
Project and U.S. President Barack Obama’s Brain Research
Through Advancing Innovative Neurotechnologies (BRAIN)
Initiative — were independently announced with the goal of
ultimately understanding how the brain works.8 Overall, the influence of neuroscience on society can readily be seen in mass
media, literature, and film.9 Last year, the discovery of neurons
that encode spatial location and enable spatial navigation (ie the
“brain’s GPS”) was celebrated with the Nobel Prize in Physiology
and Medicine.10
In this issue, the UWOMJ would like to celebrate the brain
and mind, and provide a glimpse at the current state of neuroscience in science, medicine, and society. A lot has changed since
the time of Wilder Penfield, and although neuroscience is still
in its infancy, current research and discoveries bring us closer to
understanding the mysteries of the brain and mind, and human
nature itself.
Jason L. Chan
Editor in Chief
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Care and curriculum

Does clinical empathy decline during medical education?
Victor Parchment (BA Candidate), Naomi Mudachi (Meds 2017)
Faculty Reviewer: Dr Barry Schwartz, DDS, MHSc (Division of Practice Administration)

abstract
Background: Clinical empathy has been repeatedly shown
to increase patient satisfaction and improve clinical outcomes;
therefore it forms an important cornerstone of the physician-patient therapeutic relationship. While some studies have shown
that empathy in medical students decreases over the course of
their education, other studies have contested these findings.
Purpose: This paper reviews studies and relevant literature in order to explore the relationship between medical education and clinical empathy, and in particular, the difference
in results between those studies that demonstrated a decline in
clinical empathy and those studies that did not.
Conclusion: Study design and methodology, differences
in clinical culture, and differences in curriculum were identified as three possible influences that explain the lack of consensus in the literature. This paper recommends a twofold
approach to further research in the field of clinical empathy
development. First, future studies examining this phenomenon
should focus on longitudinal designs that incorporate objective
measures and patient factors rather than relying exclusively on
cross-sectional studies utilising self-assessment. Second, medical schools should be encouraged to adopt or develop techniques to assess the clinical empathy of their students and implement solutions to mitigate a decline in empathy if required.

introduction
Clinical empathy, or “the ability of the physician to understand
a patient’s experience, to communicate and confirm the understanding with the patient and then to act in a helpful and/or therapeutic manner”,1 is central to fostering therapeutic relationships
with patients and their support network.2 Literature reviews indicate that empathy positively impacts patient satisfaction,3–5 decreases perceived distress and ultimately leads to improved clinical
outcomes.5,6 Moreover, empathetic physicians encourage patient
disclosure of symptoms leading to enhanced diagnostics4,7 as well
as improved adherence.3–5 Conversely, a lack of empathy has been
shown to have negative effects on patient care.8
Unfortunately, several cross-sectional and longitudinal studies
following medical students through their years of study demonstrate that medical students show a decline in self-reported empathy, most noticeably after their clerkship year and continuing
through residency.6,7,9–11 On the other hand, studies confirming an
empathy decline during medical education seem to be localised to
the Americas, as cross-sectional studies conducted in Iran12 and
Pakistan4 find no variation in empathy based on student year, and
studies in Japan,13 Korea14 and Portugal5 find an increase between
UWOMJ 84:1 | Winter 2015

early and later year students. These studies may cast doubt on the
notion that empathy declines over the course of medical education,
but they also point to cultural or curriculum-based factors that may
explain the difference in results.
Given the importance of empathy in physician-patient encounters, and given the uncertainty in the literature concerning the nature and severity of the alleged decline of empathy in medical students, this paper will evaluate the research to assess whether or not
clinical empathy is at risk of decline in medical students.

evaluation of the research
Analysis of the available literature revealed three main themes
which may be contributing to the lack of consensus regarding empathy decline in medical students: study design and methodology,
differences in clinical culture, and differences in curriculum. Lessons learned from these areas may strengthen study methodology
and may be used to enhance medical curriculum where necessary.
Study Design and Methodology
Any discussion regarding empathy is complicated by the ambiguity of the term; this has made the relevant research difficult
to navigate15 and created challenges when designing psychometric
tools to measure it. In developing such measures, one must consider the threats to construct validity that can arise due to variations in
how cultural communities define empathy.12–14,16
For example, it has been suggested that Japanese social cues
rely less on gestures and facial expressions when compared to their
American counterparts,13 and as such, some standards of empathic
communication may not be perfectly translatable cross-culturally.
Great care must be taken in developing tools so that they account
for such differences.
It is worth noting that the studies that did not demonstrate a
decline were cross-sectional in nature, and could be subject to cohort effects; longitudinal studies following a class of medical students throughout their education would provide a more robust data
set from which to draw further conclusions.4,5,13
Finally, all of the studies in question utilised self-report questionnaires and many used a version of the Jefferson Scale of Physician Empathy (JSPE) to construct those questionnaires. Even
though the JSPE was designed specifically to measure clinical
empathy, and has been reported to correlate with patient/observer
scores, one must consider the role of social desirability bias when
interpreting self-reported results.4,14,17
Differences in Clinical Culture
Both physician and patient expectations play an important role
when measuring clinical empathy. For example, there is much in
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the literature to suggest that patients acclimatized to an East Asian
clinical context are more comfortable sharing a vertical relationship with their physician than their American counterparts, who
may view such an arrangement as showing a lack of empathy.14,18
Behaviour in one cultural context may be seen as lacking empathy
while the same behaviour in another may be considered satisfactory or laudable. More work needs to be done understanding the
cultural differences in patient expectations before interventions
can be designed; interventions that may increase a patient’s feeling of physician empathy in a traditional American context might
instead create the appearance of “uncertainty, lack of competence,
and weakness”18 in a traditional Japanese or Korean context. This
is of particular note when patients carry their expectations across
borders, and physicians must be aware of their own cultural expectations, as well as those of their patient.
Interestingly, baseline empathy scores for medical students
were lower in the Japanese and Korean studies, compared with
American and Italian medical students.18 While the Japanese and
Korean students showed an increase in clinical empathy throughout
medical education, physicians from these populations scored lower
on empathy measures overall than physicians from the American
and Italian populations. Though outside the scope of this paper, it
would be worth investigating the shift of both groups compared to
their respective general populations to better understand the relationship between cultural factors and clinical empathy.
The clinical culture of subspecialties can also influence empathy decline. In the studies where a decline was noted, students
that indicated a preference for people-oriented specialties (eg family medicine, internal medicine and psychiatry) had higher levels
of empathy at admission and experienced less decline in empathy
than those who gravitated towards technology-based specialties (eg
radiology and surgery).10,17,19 This difference may be related to the
emphasis that people-oriented specialties place on interpersonal
communication, which may reduce patient objectification.20 Another related factor may be the increased reliance on technology in
certain fields, which shifts the focus from patients to test results.18,21
Differences in Curriculum
Each of the aforementioned studies focused on a single school,
and thus the results may not be generalisable to all schools of that
country or region. It has also been suggested that the academic culture of a school itself may play a role in the results obtained. For
example, a highly competitive school with an emphasis on research
may attract certain types of students, thus skewing the baseline results. This may have been the case in the study conducted at SeoulNational University College of Medicine (SNUCM), which is one of
the top-ranking medical schools in Korea.14
Curriculum itself may play a role in fostering clinical empathy.
The second year students evaluated during the study conducted in
Pakistan received more patient interaction, history-taking training
and examinations designed to evaluate professionalism than their
American counterparts,4 and professionalism has been shown to be
positively correlated with clinical empathy.22 This is not an isolated
effect: of the four studies that do not show a decline, all have similar curriculum profiles in regard to patient-centred and humanistic
UWOMJ 84:1 | Winter 2015

training. For example, third year students at SNUCM are required to
take psychiatric courses and higher empathy scores in the following
year may be a result of techniques learned during these courses.14
The first and second year students surveyed at Okayama University
in Japan spent only one day a week studying medical science while
the rest of the curriculum was focused on other subjects from the
arts and humanities; this early academic diversification may contribute to the eventual rise of their empathy scores later in their
academic careers.13 Lastly, students surveyed in the Portuguese
study were exposed to a curriculum emphasising patient-centred
healthcare, humanities training, interpersonal communication
skills, clerkships in urban, sub-urban and rural communities, and
frequent assessments of professionalism.5
Based on their study of medical students at the University of
the West Indies, Youssef et al (2014) theorised that a decline in empathy during later years may be attributable to an increase in stress
caused by novel challenges that typically arise during this period
of study.23 This theory correlates well with a study by Brazeau et al
(2010) that demonstrated a link between medical student burnout
and lower empathy scores.22 This indicates a potential point of curricular intervention for schools noting a decline in the empathy of
their students over time.

prescriptions and conclusions
Based on the evidence that we have presented here, whether
or not a study demonstrates a decline in empathy appears to be influenced by the sampling/study methodology used as well as the
clinical culture and curriculum to which students are exposed.
The first way to approach these findings is to focus on improving the tools and methodology underlying clinical empathy
research. Some improvements could include using controlled or
randomised controlled studies, utilising longitudinal designs, measuring patient factors or skills-based outcomes rather than relying
solely on self-assessment, and incorporating objective measures
from the patient perspective to assess whether results are reflective of future performance (eg 10-item Consultation and Relational
Empathy questionnaire).3,6,24 Critically, psychometric tools such as
the JSPE must continue to be validated cross-culturally and against
other established measures to ensure the data collected is reliable
and predictive.
The second way to approach these results is from an institutional perspective. Since few contest the value of clinical empathy,
the goal should be using robust tools to: measure empathy at the
institutional level, analyse potential weaknesses in the curriculum,
and validate interventions designed to increase empathy. It is likely
that curriculum and the wider clinical culture influence whether
or not empathy declines, remains unchanged, or increases; therefore medical schools experiencing a decline should look to schools
where such a decline is not present for methods to manage and enhance the clinical empathy of their students.
While the data on empathy change in medical students does
not currently allow for definitive conclusions, further research will
not only provide greater insight into this phenomenon, but also
raise awareness of the importance of clinical empathy for future
physicians.
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Thrombolysis & acute management of ischemic stroke
Alexander Levit (MD/PhD 2020), Brandon Chau (Meds 2018)
Faculty Reviewer: Dr Vladimir Hachinski, CM, MD, DSc, FRCPC (Department of Clinical Neurological Sciences)

abstract
Ischemic stroke causes morbidity and death in 55 000 Canadians each year. While acute supportive therapy is essential for
stabilizing ischemic stroke patients, resolution of cerebrovascular
occlusion can only be accomplished by injection of thrombolytic
agents. However, older guidelines restrict thrombolysis to within
the first 3 hours of symptom onset. This short window of opportunity for thrombolytic treatment is complicated by its inherent
adverse reactions, making it necessary to readily identify potential stroke cases, but also to diagnose accurately to avoid inappropriate treatment. In light of statistics that identify late presentation as the most common reason for stroke patients not to receive
thrombolytic treatment, and meta-analyses that now show benefits of thrombolytic treatment up to 6 hours after stroke onset,
guidelines are undergoing revision to allow larger treatment windows. This, along with continuing improvements in stroke treatment access and infrastructure, will hopefully lead to better outlooks for Canadians who suffer ischemic stroke.

It is not just a cliché: every minute really does count. On average, 1.9 million neurons, 14 billion synapses, and 12 kilometers of
myelinated fibres are destroyed every 60 seconds following a large
vessel ischemic stroke. Reminiscent of Christopher Nolan’s Interstellar, the ischemic brain can age 3.6 years for every hour that a cerebral artery is left occluded.1 Unfortunately, this is not just fiction.
Ischemic stroke is a leading cause of death and disability, a crippling
reality for 55 000 patients across Canada every year.2 While prevention is crucial, therapeutic options are especially effective when
prompt thrombolytic intervention is possible. Given the time-sensitive nature of stroke management, it is important to be familiar with
the general approach to acute stroke. We will focus on thrombolytic
therapy for ischemic stroke but first, we will review the key points
of stroke diagnosis.

diagnosis
History and physical examination offer vital information when
an ischemic stroke is suspected. Usually, presentation will include
a history of sudden onset focal neurological symptoms (Table),
though symptoms may fluctuate in severity or worsen gradually.
Headaches will occur in approximately 1 in 4 cases of stroke. For
determining treatment options, the time of symptom onset is a critical feature of the history and should be detailed whenever possible.
Ischemic stroke often occurs without pain, so many patients may
not be woken by a stroke that occurs during sleep. In this case, it
UWOMJ 84:1 | Winter 2015

is assumed that the stroke began at the last time the patient was
known to be symptom-free. Most presenting patients are alert,
though infarction of the brainstem can cause a decreased level of
consciousness. Nausea and vomiting may also occur if the brain
stem is affected.3
As many as 1 out of 8 initial diagnoses of stroke may be incorrect, so it is important to consider all of the possible mimics.4,5 Many
of these mimics will tend to have more global presentations than
most strokes, although the opposite is sometimes true.3 For example, vertigo can often present with nausea and ataxia, mimicking
the presentation of a stroke, particularly vertebrobasilar ischemia.4
However, vertebrobasilar ischemia is more likely to present with
cranial nerve deficits, such as loss of corneal sting sensation and
loss of nasal tickle, and other focal symptoms (eg diplopia, dysarthria, hemianopsia, transient global amnesia). One of the most common non-stroke referrals to stroke teams is syncope due to suspicion of brain stem ischemia, for which assessment for arrhythmias
and excessive parasympathetic stimulation can rule out more common causes of syncope. Of all stroke mimics, unrecognized seizures
followed by post-ictal paralysis or confusion may be the most common.4,5 Vigilance for a history of epilepsy and signs of seizure activity would direct appropriate investigations including electroencephalography. Other mimics include metabolic abnormalities (eg
hypoglycemia, hepatic encephalopathy), drug overdose, neoplasia,
and infection, which can be evaluated for with routine laboratory
tests.3,4
Clinical evaluation can help differentiate hemorrhagic and
ischemic strokes. Intracranial hemorrhage is more likely with the
presence of coma on arrival, vomiting, severe headache, current
anticoagulation therapy, hypertension, or non-diabetic hyperglycemia. However, imaging studies are still necessary to confidently
rule out a hemorrhagic stroke or other vascular brain lesions.4 The
current standard of imaging is noncontrast-enhanced CT, owing
to the scan’s speed, availability, and relatively low cost. The target
timeframe for diagnosis of stroke patients is to complete CT examination within 25 minutes of arrival, with interpretation complete
by the 45 minute mark from arrival.6 Laboratory tests should also
be complete by this time and to ensure this kind of efficiency, stroke
centres have to implement appropriate infrastructure.

general support & thrombolytic therapy
Acute ischemic stroke can lead to rapid patient destabilization,
even without initial overt failure of vital function, so protective
measures are imperative for the recovery of stroke patients. This
includes monitoring oxygen saturation with a pulse oximeter and
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Table: Common patterns of focal neurological impairments correlated to
region of infarcta
Dominant (left) hemisphere

• Aphasia
• Contralateral hemiparesis, sensory loss,
spatial neglect, homonymous hemianopia,
impaired conjugate gaze

Nondominant hemisphere

• Contralateral hemiparesis, sensory loss,
spatial neglect, homonymous hemianopia,
impaired conjugate gaze

Subcortical & brain stem

• Unilateral hemiparesis, sensory loss
• Dysarthria
• Absent abnormalities of cognition, language or vision

Brain stem

• Motor or sensory loss in all four limbs
• Crossed signs (ipsilateral cranial nerve &
contralateral spinal deficits)
• Dysconjugate gaze
• Nystagmus
• Ataxia
• Dysarthria, dysphagia

Cerebellum
a

• Ipsilateral limb ataxia
• Gait ataxia

Adapted from Adams et al.3

providing oxygen supplementation as needed to maintain ≥95%
O2 saturation. Endotracheal intubation and careful monitoring of
respiratory function may also be indicated if there is suspicion of
brainstem ischemia or compression.7 Myocardial infarction and
cardiac arrhythmias may develop secondary to stroke, and a 12lead ECG should be monitored for all stroke patients.3 Fever development after stroke onset is a poor prognostic factor, and studies
indicate that this should be treated with antipyretics and cooling
devices.8 Induced hypothermia has been theorized to be neuroprotective, but evidence to support this approach is still indefinite.9,10,11
The specific goal for thrombolysis and subsequent brain tissue
reperfusion is to salvage tissue in the ischemic penumbra—tissue
surrounding the ischemic core that has not been yet been infarcted.3 This is accomplished with rapid intravenous administration
of recombinant tissue plasminogen activator (rtPA), powerful
thrombolytic agents that accelerate the breakdown of the fibrin
meshwork of offending thromboemboli. Several drugs belong to
the serine protease class of rtPA (alteplase, reteplase, tenecteplase),
and all cleave endogenous plasminogen to its active form, plasmin,
which degrades fibrin. With intravenous administration of thrombolytics, 37% of patients in Canadian hospitals achieve excellent
clinical outcomes (n = 1135).12 In comparison, only 27% of ischemic
stroke patients would be expected to achieve this level of recovery
on standard therapy without thrombolysis.12,13 Excellent outcome
was defined as a return to the level of function prior to stroke, as
assessed by the modified Rankin Scale. Since these drugs are so effective at dissolving blood clots, they come with very serious risks
of hemorrhage, including intracranial hemorrhage. This is especialUWOMJ 84:1 | Winter 2015

ly of concern with hemorrhagic stroke, but it is also a consideration
in the treatment of ischemic stroke due to danger of conversion to
intracranial hemorrhage. Understandably, active or recent bleeding
are contraindications for thrombolytic therapy. Aspirin or other anticoagulants should not be given at the same time as thrombolytic
therapy, as they increase the risk of bleeding.14

looking forward
Ongoing trials are investigating refinements to thrombolytic
therapy, and the literature is very extensive and sometimes polarized. Many thrombolytics have been developed in an attempt to
improve therapeutic benefit, to expand the window of opportunity
for drug administration, and to reduce the rate of adverse events,
namely hemorrhage. New drug candidates are often theorized to
improve thrombolytic therapy because of increased biological halflife or improved target specificity. However, a Cochrane meta-analysis did not find adequate evidence to indicate any superior alternative to alteplase (0.9 mg/kg), the only FDA approved agent that is
indicated for acute ischemic stroke.15 Similarly, intraarterial thrombolytic administration was theorized to reduce adverse events because of more localized delivery and lower therapeutic doses, but
this was also found to be unsupported.15 The potential advantage of
intraarterial over intravenous administration may be offset by the
delay in drug delivery because of relative procedural difficulty.
Although initial clinical trials on thrombolytic therapy found
unfavourable outcomes in patients greater than 80 years of age and
patients that have had symptoms for longer than 3 hours, more recent studies have had success with expanded inclusion criteria. The
most recent Cochrane review suggests patients older than 80 years
equally benefited from thrombolysis, and while treatment within
3 hours is still far more optimal in all age groups (OR 0.66, 95% CI
[0.56 – 0.79], n = 2187), treatment within 6 hours still significantly reduced death or dependency (OR 0.84, 95% CI [0.77 – 0.93], n
= 6729).14 Unchanged since 2001, The Canadian Asssociation of
Emergency Physicians still recommends rtPA treatment within
3 hours only, while the 2010 Canadian Best Practice Recommendations for Stroke Care indicate that rtPA can be given within 4.5
hours of symptom onset.16,17 Centres involved in thrombolysis protocol research may expand the window for treatment, so differences should be expected. London Health Sciences Centre currently
offers rtPA treatment within 4.5 hours of symptom onset to patients
of any age.
Despite the advances in patient outcomes, only 6.1% of ischemic stroke patients received thrombolysis throughout Canada’s
provinces in 2008-2009 (n = 9588). The territories were excluded in
this study, leaving us only to speculate on the challenges for stroke
management in these regions. Rates for utilization of thrombolytic agents were variable: comprehensive stroke centres treated 11%
of ischemic stroke cases with thrombolysis, compared to 5.7% in
primary stroke centres, and just 1.0% in other centres. In this same
study, the reasons documented for not treating with thrombolysis
included patients presenting too late in 42% of cases, neurological
deficit too mild in 24%, clear medical contraindication in 5%, and
no reason was documented in 25%.18 While refining the eligibility
criteria for rtPA treatment is important, these variable utilization
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rates indicate that serious infrastructure improvements will also
have to be made in our ability to identify and respond to ischemic
stroke events. With prompt identification and management, further
improvements in thrombolysis, and national coordination of stroke
care, we can look forward to better prognoses for acute ischemic
stroke.
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A brief review of neuroimaging using functional
magnetic resonance imaging (fMRI)
Stefan Rodic (Meds 2018), Pei Jun Zhao (Meds 2017)
Faculty Reviewer: Dr Ravi Menon, PhD (Department of Medical Biophysics)

introduction
Since the turn of 21st century, improvements in medical imaging have been considered one the greatest triumphs in the history
of modern medicine. Advancements in magnetic resonance imaging
(MRI) have allowed physicians to peer into human anatomy with
ever greater resolution. MRI works through the magnetization
of hydrogen protons in the body followed by short bursts of radio
waves which are reemitted and subsequently detected for noninvasive neuroimaging. However, this technique was limited to forming
static structural images without providing real-time information on
brain activity or function.
Blood-oxygen-level-dependent (BOLD) MRI, also known as
functional MRI (fMRI), overcomes these limitations and enables
physicians to visualize the activity of the brain.1 Changes in blood
flow act as a marker for metabolic activity and thus neuronal firing,
as blood flow increases to more active regions. BOLD was first developed in 1989 and demonstrated that deoxyhemoglobin (a natural
paramagnetic substance) could act as contrast agent.2 In this article,
we will review the advantages and limitations of fMRI, while introducing some developments in the field.

indications
Currently, fMRI is mainly used for research purposes but there
are a growing number of specialized clinical indications. For example, prior to neurosurgery fMRI may be used to map critical areas
of the brain such as the language centres.3 It can also be used to
assess brain function of patients with seizures.4 Some studies indicate that fMRI remains promising for use as a detection tool for
the diagnosis of early Alzheimer’s disease.5,6 This technology may
also have wide-ranging applications for common psychiatric disorders. Patients with major depressive disorder, schizophrenia, attention-deficit hyperactivity disorder and autism were distinguished
from the resting state of controls using BOLD imaging.7-10
However, brain activity is often variable, so clinical interpretation given the patient’s context is essential. Clinicians should also
consider the effect of sedation, medications and anxiety on the hemodynamic response and subsequent signal. fMRI can also be dangerous for people with pacemakers and metal valves. Nevertheless,
as a fairly young technology, fMRI and its variants have the potential to become a gold standard imaging tool in neuro-medicine.1

advantages
When compared to other non-invasive functional imaging
techniques, the central advantage of fMRI is its high spatial resolution in the millimeter and potentially submillimeter range.11,12
UWOMJ 84:1 | Winter 2015

Its ability to distinguish between smaller regions of activity is superior to positrom emission tomography (PET) and much greater
than magnetoencephalography (MEG) or electroencephalography
(EEG), which have spatial resolution on the order of centimeters.13
Although seemingly insignificant, such a difference in resolution is
vast considering that a few square millimeters of grey matter may
contain millions of neurons, constituting billions of synaptic connections.
fMRI can also detect activity deep inside the brain in three dimensional space, while EEGs generally reflect global neural activity on the cortical surface. Compared to PET, BOLD imaging does
not require radioactive contrast agents or metabolites and provides
higher temporal resolution.14 Thus, it is a relatively safe imaging
tool, even for children and pregnant women. Along with advancements in computational software, multivariate analysis in fMRI allows many small units of the brain to be tracked in unison, without
simply averaging the activity of whole brain regions together.1 Instead of having large areas of average brain activity, the use of these
three-dimensional pixels (voxels) allows for greater spatial resolution and reduced noise.
The critical assumption that hemodynamic response indicates
neuronal activity has been questioned, yet there is a great deal of
evidence that supports the validity of blood-oxygen-dependent imaging. Electrode implants have confirmed that neuronal activation
correlates with BOLD MRI recordings.15 Similarly, recent advances in optogenetics have allowed the activation of specific neuronal
circuits that have also been found to match the fMRI signal.16,17 Although the scanners themselves are costly, they are common and
the same platform can be used for both functional and anatomic
imaging.14

limitations
Despite being correlated with the electrical activity of neurons, fMRI is an indirect imaging method. Often studies are able
to demonstrate correlation of a brain region with a given task or
condition but cannot establish causation. Subtle small-scale changes in neuronal activity likely go undetected as they do not induce a
significant change in blood flow, while routine hemodynamic variations may generate noise.14 fMRI cannot distinguish the number
of neurons firing. A hypothetical circuit may have excitatory and
inhibitory signals that cancel out, but this would only be detected
as generalized neuronal activity.
Hemodynamic responses are inherently slower than electrochemical ones, which can be detected by MEG/EEG in the millisecond range.13 The temporal resolution of fMRI being on the order of
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2-3 seconds means that the technique is not truly real-time.18 Moreover, there is generally a trade-off between spatial and temporal
resolution since it takes more time to acquire images with smaller
voxels.14
In addition, the interpretation of fMRI is statistically demanding. The use of different statistical techniques can lead to subjective
interpretations. Correction for multiple comparisons is absolutely
necessary to reduce false positives. One humorous study demonstrated false-positive brain activity in a dead salmon when multiple
comparison corrections were not made.19
Finally, there are currently few studies for practical clinical
use, although research is actively being conducted in this area. To
obtain higher resolution, MRIs with stronger magnetic fields are
being developed. Although the genotoxic effects of a static magnetic field have been demonstrated at the cellular level, they are
thought to be negligible.20
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fMRI to guide EEG signal acquisition to map the electrical activity
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conclusion
Since it was first described by Ogawa et al, fMRI technology
has rapidly developed as a noninvasive method to map brain activity. While it remains for the most part a research tool, fMRI has great
potential to become widely adopted in clinical medicine. Already,
practical applications such as localizing key brain regions prior to
surgery exist. With advancements in MRI technology and increases
in computational power, fMRI will be an important player in the
field of neuroimaging in the future.
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introduction
Advances in neuroscience and biotechnology in recent decades
have opened up unprecedented possibilities for altering and modifying the human brain to enhance cognitive and mental functions.
Although one gets the impression that much of the current neuroscience research in “mind enhancement” is still only nascent, in the
case of certain studies it is already possible to see clearly their implications for—and consequently their challenges to—some of our
current medical, legal and cultural conventions. Take, for instance,
the example of recent research in a neuroscience field called optogenetics. In 2013, a group of neuroscientists developed a way of
inducing a “false memory” in experimental mice. These researchers had identified a specific population of neurons in the dentate
gyrus of an animal subject’s hippocampus, known to be involved in
memory formation and storage, that was naturally activated whenever the animal was exposed to painful stimulus (eg electric shock).
These neurons would be reactivated in the future in response to the
same or similar context, even in absence of the painful stimulus,
producing a fear response—that is, because a “fear memory” had
been formed. By reactivating these same cells artificially (using
light energy—hence the name, optogenetics) in a different context
than the one used to condition the original fear memory, the fear
response could again be elicited in the animal subject, this time to
an entirely new context—thus forming a “false memory.”1 If extrapolated to the human brain, these and similar discoveries in nanotechnology, biotechnology, information technology, and cognitive
science (NBIC), open up exciting and in some cases potentially
alarming new possibilities. The imaginable applications of such
techniques span a spectrum, from medical therapies that could
cure individuals traumatized by abuse to the ominous spectre of
a government reprogramming the minds of criminals and perhaps
political dissidents.

cognitive liberty
Recently, an attempt has been made to confront the issue of
NBIC technology as a moral-philosophical problem by articulating
the novel ethical concept of “cognitive liberty.” According to Sententia, a leading neuroethicist on this subject, cognitive liberty is
the idea that every person has a fundamental right not only to think
independently (a right already contained in liberalism’s commitment to ‘freedom of thought,’ as defended by J. S. Mill), but also
“to have autonomy over his or her own brain chemistry.” It would
seem to follow that, as a fundamental right, cognitive liberty would
require strong legal protections for the private use of neuroenhancement (NE) technologies.2 This view of cognitive liberty as a
UWOMJ 84:1 | Winter 2015

fundamental right directly challenges a number of contemporary
norms. For instance, it seems to imply the need to protect the recreational use of psychotropic drugs, a practice that is currently illegal
in many places.
From a philosophical standpoint, there are opposing stances on how NE shapes the definition of being a self: the essentialist viewpoint that NE compromises what it means to be a person,
and the existentialist opinion that NE is a choice people can make
as the agents of their own development. According to theologian
Alan Watts, there is a longstanding view within Western culture of
the person as an “individual, self-determining, responsible ego.”3
Essentialists would argue that NE jeopardizes this definition of
personhood and compromises the “authenticity of persons” by interfering with individuals’ natural journey of self-discovery and
personal growth.4 Individuals might confuse their understanding
of themselves as they are with that of their neuroenhanced selves.
Conversely, existentialists would support NE, as they believe that
acting as the responsible agent of one’s development is a fundamental part of being a person. It follows that actively shaping who one
wants to be includes how one wants to think, under the influence
of NE or not. So long as these NE interventions pose low risk to
health, should individuals not have the right to benefit from their
enhancing effects?3
Ethical issues of cognitive liberty also concern the social impact of NE. On one hand, society as a whole might benefit from
NBIC-related medical innovation; thus, one could argue that there
is an obligation to pursue research into NBIC-related technologies
such as optogenetics. Yet one might also have reason to fear that
unequal access to memory- and attention-improving tools could increase social inequality within our society. In an era of competitive
job markets and information overload, those who can access and afford NE may be perceived as having an unfair advantage over those
who cannot. Ethicists have raised concerns over how increasing the
standard of cognitive fitness within such a competitive environment might actually impede rather than enhance cognitive liberty,
as non-users will feel pressured to use NE in order to keep up with
their cognitively advantaged peers.4

legal and social dimensions
Cognitive liberty is implicit in the freedoms of thought and
action.3,4 However, proponents of NE argue that cognitive liberty
and its boundaries must be explicitly defined within positive law
in order for individuals to be protected in their elective use of NE
and protected from government imposition of NE.3 Proponents of
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elective NE use would argue that the value society places on bodily
integrity (the autonomy of persons over their own bodies) supports
the legal right to cognitive liberty.5 Our legal system allows individuals to engage in behaviours that put the physical body at risk, such
as extreme sports. Instead of prohibiting these activities, regulations are put in place to ensure safety and informed consent, and
the onus is placed on the individual to determine whether the behaviour is appropriate.4 Given that individuals are allowed to make
informed decisions regarding behaviours with potential physical
harms, how can behaviours with neurologic effects be criminalized? After all, the nervous system is part of the physical body. This
question is especially relevant to NE with low risk-profiles, as the
harm principle, which states that power cannot be exercised against
a civilized community’s will unless it is to prevent harm, is a precursor to criminalization.3,6 The counterargument to this notion is
that mind and body are distinct, as are our understandings of these
entities. Injury to the body is well researched, whereas the definition of “illegitimate mental harm” remains unclear.4 Critics of NE
would argue that it is counterintuitive to draft policies in support of
NE while our understanding of the mind remains limited and fully
informed decisions about its use cannot be made. Nevertheless, as
our knowledge of brain function is expanding, policy-makers must
consider explicitly defining cognitive liberty within positive law in
order to lay the foundations for safe and regulated use of NE in the
future.2
Although no court has yet ruled on a cognitive liberty case,
there are precedents in other areas of constitutional case law that
help us predict how courts might decide on the question of cognitive liberty in the future. Constitutional guarantees of individual
rights in Canada and the United States strongly reflect the harm
principle, yet the courts have not applied this principle in a consistent or unqualified way. Rather, the courts have restricted individual liberty in a wide range of areas of private life, such as prohibiting
the recreational use of some drugs (methamphetamines) and not
others (nicotine and alcohol); allowing the sex industry to exist,
but banning prostitution; and allowing self-harm, but only up to a
point—namely, not to the point of suicide. The reason for this is that
the courts have recognized other principles enshrined in the law
that are distinct from the harm principle. Section 1 of the Charter of
Rights and Freedoms accepts that “reasonable limits” to fundamental individual freedoms may be prescribed by law in order to uphold
a “free and democratic society,” and in accordance with this constitutional provision the Supreme Court of Canada (in R. v Oakes) has
established precedents for limiting individual freedoms as a way of
defending “collective goals of fundamental importance.”7 Thus, for
example, in 1993 the Canadian Supreme Court ruled in R. v. Tremblay, a case involving sex trade workers in Quebec, that the law may
restrict individual liberty in accordance with a “community standard of tolerance”—in this case, for acts of “anti-social” indecency.
The court considered this community standard to be a legitimate
imposition on individual liberty that was consistent with a liberal
constitution.8
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In these and other such cases, the courts have recognized the
need to balance the common good against individual autonomy, following a long tradition of democratic thought, from Aristotle up to
the intellectual founders of the Anglo-American republic, that has
understood a functioning political order as deriving at least some
of its stability from a certain moral consensus or majority opinion—
whether that opinion is more enlightened, or less.9,10 The question,
then, is whether it is likely that the majority moral opinion can now
or will in the future be able to tolerate such practices—psychotropic
drugs, optogenetic memory alteration, cognitive enhancement—as
are defended by advocates of cognitive liberty. For now, it can only
be said that it will likely be able to tolerate some (eg certain medical
therapies), but not others (eg hallucinatory recreational drugs, or
their NE equivalents). This is complicated by the possibility that
the majority moral opinion of a community may change over time.
Democratic regulation of NE will continue to be a challenge within
our ever-evolving society.
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introduction
The word “altruism” is commonly ascribed to those who pursue a career in healthcare. However, looking at medicine through
the lens of altruism shuts our eyes to the inherent humanity of
physicians and limits our ability to provide optimal care. It is unreasonable to expect that physicians will (whether consciously or
unconsciously) always prioritize ideal health outcomes in the face
of varying incentives. This is especially true given that there is no
single universally accepted definition of what “ideal health outcomes” would be. Unsurprisingly, a recent Cochrane review of the
subject found that physician compensation models do in fact influence behavior.1 How then can we align physician incentives with
quality care?
There are four discrete compensation structures in use, with
a blend of these commonly employed. Fee-for-service (FFS) models compensate doctors a set amount for each service they perform.
Capitation models offer compensation based on the total number
of patients under a doctor’s care, regardless of how frequently each
patient seeks care. Salary models offer physicians fixed remuneration that does not vary based on the services they perform nor patient demographics and are commonly employed by hospitals and
community health centers. Pay for performance (P4P) models provide direct financial incentives for meeting certain specific treatment goals.2,3
In Canada, 40% of physicians primarily receive FFS payments
(>90% of their income), 10% primarily receive salaried payments,
and 1% primarily receive capitation compensation. 33% of physicians receive a blend and about 16% receive the majority of their
compensation through other forms, including P4P/incentives,
short term contracts, and per diems.4

health outcomes
There are several key health outcomes which are affected directly by physician remuneration schemes. The most significant include quantity of patient visits, quality of patient care, efficiency of
resource use, and physician acceptance of complex patients.2,3
The effect that a given compensation scheme has on health
outcomes is closely correlated with the “variability” in remuneration received, which is a representation of a physician’s control
over their own income. FFS and P4P schemes are considered widely variable, while salaried systems are considered fixed. Capitation
models fall somewhere in between, but generally produce outcomes more in line with salary models.4 This establishes a spectrum
by which we can compare the different models.
FFS models give physicians considerable control over their
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earning potential but in so doing create a mixed bag of externalities.
It creates an incentive for physicians to provide a higher quantity of
treatment to patients, as payment is dependent on the quantity delivered. FFS also incentivizes physicians to perform a high volume
of procedures and tests that have greater fees attached to their provision. By extension, FFS unfortunately encourages the provision of
unneeded investigations and treatments, undermining the principles of resource management, and potentially biasing physicians in
favor of carrying out more expensive actions when a simpler option
may suffice.5-7
Capitation models are perhaps the best at reinforcing the importance of preventative medicine and resource management.
However, this model does not offer additional remuneration for
seeing the same patient multiple times, so a physician is unintentionally rewarded for seeing a patient as little as possible. The result
is an emphasis on prevention, the conservation of resources and the
use of treatment plans that require little management and have fewer side effects and complications. Potential negative consequences
include an adverse impact on meaningful doctor-patient relationships, and a decreased incentive to see the same patient multiple
times (even when warranted) or accept complex cases.7-13
Salary models reimburse physicians independent of the number of patients they see, the amount of time spent with patients, and
the type of services provided. Monetary incentives are significantly
limited, so there is no financial motivation for a physician to work
harder than the minimum or to conserve resources; however, on
the positive side this also means there is no financial deterrent to
spending more time with patients, taking on difficult patients, or
utilizing more intensive and involved treatment regimes.5,14
P4P models seek to correct many of the problems inherent to
FFS, capitation, and salary systems. Since 2002, Ontario has gradually introduced more P4P measures, particularly within the realm
of family medicine. Such measures include incentives for providing
monitoring tests to diabetics (HbA1c levels, cholesterol levels, and
eye tests), administering flu shots to vulnerable populations, and
many others. A recent Cochrane review showed that 6 of 7 published studies on the effectiveness of P4P showed clear positive impacts on patient outcomes.15 The actual magnitude of these impacts
however were somewhat modest, and some research has pointed
out that some specific types of P4P (for example those associated
with mental health and drug abuse) are in need of optimization
before they become cost-effective.16 Despite this, the effects when
these incentives are fine-tuned and implemented on a broader scale
are certainly worth investigating.
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There are several studies that seek to quantifiably contrast
physician compensation models. An analysis of family physician
behavior showed that primarily-FFS physicians spent a mean 37
hours seeing approximately 134 patients every week. In comparison, salaried physicians spent only 30 hours seeing 72 patients per
week. Physicians compensated through capitation fell between
these figures spending 33 hours seeing 96 patients. Thus, the less
variable the payment scheme, the fewer hours worked and number
of patients seen.18
A study by Dumont (2008) showed that although the number
of services provided was found to decrease with the rigidity of the
payment scheme, the actual amount of time spent performing each
service increased, supporting the notion that there may be an inherent balancing of quantity versus quality across payment schemes.17
Interestingly, salaried and mixed compensation physicians appeared to use this extra time to pursue teaching or research interests, with a twofold propensity to engage in these activities compared to FFS physicians.14
It was found that doctors operating under less variable payment schemes (eg salary) accepted more complex patients, including Aboriginals, low income patients, and those suffering from
substance abuse, mental health problems, and/or homelessness.5-11
Salaried physicians saw 2–3 times more complex patients on average than FFS physicians, while mixed compensation physicians saw
approximately 1.5–2 times more than FFS physicians.17
In a general sense, the literature supports the theory that more
fixed models of compensation emphasize preventative care, following the logic that healthier patients are seen less often, minimizing
work for healthcare providers. Resource efficiency is also significantly improved in more fixed models with fewer unnecessary consults, procedures, and testing. However, more fixed models see a
conspicuous decrease in number of patients seen and hours worked
as a whole, as the financial incentive to be productive by that measure is no longer present.4

conclusion
With some overlap, each system creates a host of beneficial
and deleterious incentives for physician behaviour. The ideal compensation structure would strike a fine balance between these
behaviours in optimizing key health outcomes. This ideal model
would motivate physicians to see a large enough number of patients
to reduce barriers to access, but small enough to ensure each patient receives adequate time and attention. It would ensure doctors
do not discriminate against patients for being too complex, and
ensure the feasibility of spending lengthy amounts of time with
patients who require it. It would also create strong incentives for
efficient resource use, limiting the provision of unneeded services.
Since the practice of any two doctors within the same specialty
can vary widely, a rigid salary model is not a practical nor equitable
choice for the majority of physicians. A salary model is likely only
appropriate as a niche form of compensation for certain practice
types like emergency physicians, rural doctors with a small patient
base, and some academic physicians.
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Capitation, although forward-thinking in terms of prioritizing
preventative care, encourages a potentially hazardous mindset—
undermining the doctor-patient relationship and decreasing the
frequency of contact points with the healthcare system. Current
data supports the notion that capitation may be better suited playing a role as part of a blended arrangement than as a sole method of
remuneration.
In the short period of time P4P has been in use, it has been
utilized largely as an experiment of limited scope, but the results of
this experiment are quite promising.18-23 More research should be
done to determine what services are in need of incentivizing, and
what magnitude of incentive motivates behavioral shifts. A harmonized FFS-P4P blend represents a tremendous opportunity to revolutionize medical care.10,24,25 Change is always difficult, but such
a change would likely be popular for both physicians who would
gain increased autonomy and patients who would benefit from improved outcomes. If Ontario could garner enough political capital
to embrace such a change in policy, it has the opportunity to become a leader in applying economic principles to the provision of
medical services and quality care for patients and families.
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What kills us and what costs us
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disease burden: a changing landscape
Over the 85 years this journal has been publishing, medicine
has adapted to the changing landscape that is disease burden. In
1930, the majority of diseases that medicine fought were infectious
in nature. Influenza, pneumonia, tuberculosis, and gastrointestinal
infections were the top killers. After 85 years of scientific advancement, infectious diseases have become well controlled in the developed world, and the population no longer fears these ailments.
In 2015, different beasts threaten our lives—heart disease, cancers,
and chronic airway diseases comprise the majority of our disease
burden.1 Valar morghulis—all men must die. As medicine saved patients from acute conditions, they began living long enough to die
from chronic diseases. As the disease burden shifted, so too did the
attention and anxiety of the population, which in turn shifted one of
the most important drivers of medical progress: funding.

a funding disparity
According to Jones and colleagues, the“goal [of medicine] should
be an integrated policy under which health care and public health
programs together fully address the disease burden,”1 This implies
that funds should be allocated in proportion to the disease burden
they represent; for example, since heart disease is the major contributor to disease burden in North America, it should receive the
greatest amount of funding. However, this is not the case. According
to the NIH, while heart disease causes more deaths than any other
disease, in 2006 it received only 3.3% of NIH funding ($398 million), while HIV/AIDS, with a prevalence ten times lower, received
seven times more (~$2.9 billion).The funding disparity is pervasive:
together, HIV/AIDS, diabetes mellitus, perinatal conditions, dementia, and alcohol abuse account for 49% of NIH research funds, but
none of these conditions are listed in the top ten causes of mortality.2

als ice bucket challenge – a case in point
This funding disparity extends beyond government funding
to publicly raised charity funding. The most recent example of a
disconnect between disease burden and funding raised through
charitable donation is the viral phenomenon of the ALS Ice Bucket Challenge. Amyotrophic lateral sclerosis (ALS), also known as
Lou Gehrig’s Disease for the baseball player who made it famous,
is a progressive, incurable, neurodegenerative disorder causing
muscle weakness and eventual death. It is the most common form
of motor neuron disease and upon diagnosis, it has a median survival of 3-5 years. Prevalence rates range between 2.7 and 7.4 per
100 000 across North America and Europe, with the disease being
slightly more common in men (M:F ratio of 1.3-1.5:1). 3
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ALS recently made waves in the media through a viral fundraising campaign involving filming the dumping of a bucket of ice
water on someone’s head in an effort to promote awareness of ALS
and subsequently raise money for research. Most videos end with
a challenge to others to follow suit.
The phenomenon began in Florida in July 2014 when a local
golfer, Chris Kennedy, was nominated to do the Ice Bucket Challenge or donate money to a charity that benefitted a local child
with cancer. When Kennedy passed the challenge along, he chose
a charity benefitting ALS because he had an afflicted relative. A
video posted to YouTube on July 15, 2014 appears to be the first
incidence of the Ice Bucket Challenge being connected to ALS.
Through social media, the trend exploded and spread across countries and organizations.4
According to CBC, more than 260 000 Canadians took part
in the Ice Bucket Challenge and raised over $16.2 million for ALS,
~$10 million of which will go directly to research, and ~$6 million
of which will go to supporting those living with ALS. The Canadian government also contributed $10 million to ALS.5 This is undoubtedly an impactful contribution but the Ice Bucket Challenge
is wrought with issues.
Paradoxically, the usual challenge is to perform the Ice Bucket Challenge within 24 hours or make a charitable contribution
to ALS, in other words allowing people to forego donation if they
complete the challenge. Many people throughout the campaign
raised concerns, especially since every video showing the challenge being completed seemed to imply that dumping cold water
on your head is preferable to donating to ALS. Several individuals
suffering from ALS have also spoken out that the campaign reduces a debilitating and lethal disease to a social bandwagon onto
which people eagerly jump without any real regard for its purpose.6 However, there is a more worrisome issue at the heart of the
ALS Ice Bucket Challenge.
According to Statistics Canada, the number of Canadians reporting charitable contributions on their income tax is decreasing
(down 0.6% from 2010 to 2011), suggesting that fewer people are
donating money to charity. However, the rise in charitable contributions suggests that fewer people are donating more. Further, only
15% of Canadian donations are to healthcare organizations, amounting to $1.59 billion. Charitable donations are affected by economic
conditions such as the recent economic downturn, suggesting that
the surge in funding for ALS may represent an equal decrease in
contributions to all other healthcare charities.7,8 This opportunity
cost is the most troubling aspect of the Ice Bucket Challenge.
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In 2011 (most recent data), 47 627 Canadians died of heart disease, accounting for 19.7% of deaths, yet the Canadian Heart and
Stroke Foundation received only $114.5 million in fundraising donations, equivalent to approximately $2404 per individual death.9,10
By comparison, between 700 and 1100 Canadians die of ALS each
year, while the Ice Bucket Challenge alone (not counting donations
outside of the challenge) raised $16.2 million in Canada; equivalent to between ~$16 200 and ~$23 150 per individual who died.5,11
Moreover, economic costs due to cardiovascular disease in Canada
in 2000 totaled $22.2 billion, representing 17% of all hospitalizations (2005-2006) and 10% of all visits to community physicians
(2007).12 Contrast this with ALS, with an economic burden amounting to approximately $182 million.13 The discrepancy between what
kills us and what costs us, and where we donate is a costly one, in
terms of both dollars and lives.
Of course, the question must be raised: if we divert funding
to the most lethal and burdensome diseases, what becomes of the
rare diseases like ALS? Research and treatment for rare diseases remains incredibly important, and funding is scarce by comparison
to the major destinations of Canada’s health research funds. The
top disease groups funded by Canada’s health research funding
agency, the Canadian Institutes of Health Research, are cancer, diabetes, cardiovascular disease, and respiratory health, representing
the major disease burden in Canada.14 This means that rare diseases
like ALS need to be funded almost exclusively by charitable contributions. In fact, ALS Canada has successfully raised substantial
amounts of money towards research. In 2013, over $3.8 million was
raised to support ALS research—a modest sum compared to the
~$16.2 million raised by the Ice Bucket Challenge alone—however,
one that is more in keeping with the proportional impact of ALS on
the population.15

conclusions
If we, as a society in Canada, wish to maximize the utility of
our charitable donations, we might aim to be better informed as to
what health problems are most pervasive and costly. The greater
good of society should factor into decisions about where to direct
charitable donations instead of relying solely on emotional or social
motivations. Addressing this requires appropriate and balanced education. The recent ALS Ice Bucket Challenge phenomenon served
as a great success for the fight against ALS, raising both money and
awareness of the disease. However, it may represent a setback in the
fight of society at large against the modern, chronic burden of disease. The goal is not to eliminate all funding for ALS, but rather to
fund all diseases in proportion to their prevalence, economic cost,
and mortality. A broad-minded society would attempt to erase the
discrepancy between the diseases that kill us and cost us, and those
which garner our attention. The final decision however, rests firmly
in the hands of the donors.
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“

In a hospital, the body is divided into departments. One department for the ear, nose and throat, one for the eyes, one for the
stomach and the intestines, one for the sexual organs, one for heart
and blood vessels, and one for the soul, which is treated in the psychiatric wards.
— Karl Ove Knausgaård, The Other Side of the Face

As medical students trained with a mind for science, it is sometimes difficult to consider the human body as anything other than
a series of anatomical parts. It is as if the human body is a great,
complex machine that begins ticking early in the life of the embryo,
and continues its autonomous functioning until the end, when system by system, the machine will slowly dissemble and finally lay
itself to rest. The comparison of the human body to machine is
called mechanization, and it is something that people have been doing since the 17th century, the mechanical century. Thinking of this
kind is closely linked to materialism—a philosophy that attributes
all phenomena, including mental phenomena and consciousness, to
be the result of material interactions—and largely informs the way
we understand the brain and mind today. When materialism influenced the understanding of the brain and mind during the 17th century however, it posed a problem for Descartes, who was trying to
accord the presence of a consciousness with the theological principles of the time. Cartesian mind-body dualism considered thought
processes to be distinct from the body-machine, and it ascribed the
thinking properties of the mind to an immortal and immaterial soul.
The brain, specifically the pineal gland, was the seat of the soul. The
soul was an individual’s connection to the heavens, and therefore
not reduced to the materiality of the body.1
While the consideration of the soul with respect to the brain
and mind may seem strange to the scientific-minded medical student, it is not an alien concept in medicine. Consider the two specialties that deal primarily in the brain and mind, neurology and
psychiatry. Materialism is recognizable in neurology: a neurologist
locates aberrant anatomical lesions throughout the nervous system
and is generally able to explain neurological disease on the basis
of objective findings and sound physiological reasoning. Mental illnesses, on the other hand, are quite unique in that they are almost
exclusively characterized by subjective symptomatology and rarely
on discrete or objective findings. At the same time, we recognize today that mental disorders can manifest with bodily symptoms. Not
unlike Cartesian dualism then, mental illnesses have required the
framework of a conceptual separation of mind and body. Descartes’
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“soul” may not have disappeared from our mode of thinking after
all, but instead, as Francis Azouvi suggests in an essay titled “Physique and Moral,” the concept of the soul may have simply been replaced by the psychological.1
The division between brain and mind had not always been so
apparent in medicine. It was not until the 19th century that medicine of the brain and mind truly diverged into the two separate
specialties of neurology and psychiatry. As neuroanatomists were
able to locate lesions related to specific diseases, the explanation
for neurological illnesses became increasingly anatomical; likewise,
the understanding of germ theory and use of microscopy enabled
infectious disorders of the mind, such as neurosyphilis, to be understood and treated definitively. Yet, psychiatric illness that could not
be placed in the anatomical or physiological realm remained, and
the understanding of the etiology of those mental illnesses was still
heavily influenced by the tremendous optimism for materialism
at the time.2 It is not surprising then, that the various treatments
offered at asylums were somatic in nature—aimed at correcting a
flawed nervous system using methods such as hydrotherapy, electrical stimulation, and rest.3 But in the late 19th century to early
20th century, the understanding and treatment of mental disorders
would begin to look to the soul, or as it would come to be known,
the psychological.
Psychoanalysis has probably been most famed and subsequently defamed by the work of Sigmund Freud, although several other
prominent neurologists, psychologists, and psychiatrists have made
major contributions to the psychoanalytic movement and its resultant schools of thought. In the absence of disease-specific brain
abnormalities, proponents of psychoanalysis recognized that some
illnesses appeared to have no discernable organic basis, and theorized that psychological causes originating in childhood experiences and the unconscious were the root of mental disease. Treatment
was thus focused on techniques such as dream interpretation, free
association, or transference, which did not aim to alter a physical
aberration related to mental disease, but rather to subjectively explore the mind. The immaterial nature of a patient’s “psychology”,
therefore, was investigated and manipulated in order to diagnose,
treat, and sometimes cure mental disorders.
At the turn of the 20th century, the connection between the
body and mind in the history of medicine was not well defined. Both
brain and mind had been implicated as the cause for mental and
somatic disorders, and manipulating both the body and the mind
had been considered as treatment regimens. Today, it is clear that a
more modern understanding of the brain and mind incorporates a
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unity between the two; thus over the course of the 20th century, we
would come to see the divergent relationship of the brain and mind
converging once again in medicine.
The union of the structural and abstract theories of the brain
and mind began in the late 19th century, but did not come to popular attention until the 1930s.4 In 1935, the first frontal lobotomy was
performed in Lisbon, Portugal by Egas Moniz, a professor of neurology, and Almeida Lima, a surgeon. The principle of the surgery
was based on research that showed the association of the frontal
lobes of the brain with temperament and behavioural control. Proponents of lobotomy surgery believed that dysfunctional behaviour
was caused by pathological material located in the frontal lobes. Ablating the pathological tracts of the frontal lobe was the goal of the
therapy. The side effects from the procedures performed were numerous: while some patients became more docile after the operation, others experienced an increase in impulsive behaviour, lack of
initiative, and reduced ability to think or plan clearly. Effectiveness
of the procedure was strongly debated, and it was popularized by
the media as one of the greatest medical blunders of the time; however, though infamous, frontal lobotomy has contributed greatly to
the study of mind and behaviour, particularly by demonstrating the
role of neuroanatomy in human psychology.5
Three years after the first lobotomy surgery was performed
in Portugal, two Italian physicians, Lucio Bini and Ugo Cerletti,
completed the first session of electroconvulsive therapy (ECT) on
a catatonic patient. This initial use of ECT relied on the understanding that electrical stimuli could be used to induce seizures in
order to treat psychiatric abnormalities. The 1938 treatment was
a success, and even though the exact mechanism remains elusive,
ECT is used today for treatment of major depressive disorders in
select patients.6 The use of ECT was closely followed by treatments
established in psychopharmacology. The introduction of psychopharmacology began in the early 1950s, with the first wave of psychotropic medications providing a treatment option for previously
untreatable psychiatric conditions.7 The therapies were based on
an understanding that neurochemical imbalances in the brain can
precipitate psychological disorders, and offered yet another physiological mode of viewing the interaction between brain function and
mental phenomena.
Today, it is recognized that a combination of psychotherapy,
medical therapy, and even surgical therapy can be effective in treating mental illnesses.8 But unlike a pathogen being eradicated by an
antibiotic, or a structural defect being corrected, individual patient
responses to psychiatric treatments are unique; that is, those that
respond to some therapies may not respond to others, and the response cannot always reliably be predicted. In light of these enduring limitations of modern medicine, it causes one to question how
far we have come from the lobotomy surgeons of the past.
The scientific investigation of the brain and mind has made
great strides over the past century in order to advance the study of
mental disorders. Improvements in surgical techniques and imaging modalities will only act to further advance the understanding of
the brain and mind. The trouble of course is that there is still much
to understand before we can arrive at a complete understanding of
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mental disorders. The Diagnostic and Statistical Manual of Mental
Disorders (DSM) is just one example of how psychiatric medicine
is still largely reliant on subjective symptomatology. Despite the
impressive research in functional neuroanatomy and neurobiology
being undertaken, there still does not exist a laboratory test, or diagnostic imaging that can reliably identify psychiatric illness. This
may be because the brain and mind is one of the most complicated
areas of medicine that humans have attempted to understand. No
other anatomical structure contains such a vast amount of information transmission to decode. If one considers that the knowledge
we currently have may represent only the tip of the iceberg, the fact
that many of the treatment regimens we use today work for patients
can seem miraculous. So if the discovery of how the mind works is
still ahead of us, we must somehow create a model of the brain and
mind that does not rely on the purely physical or the purely psychological. It seems that despite our vast increase in knowledge since
the time of Descartes, not much has changed in the fundamental
theory of body and soul.
In A Scandalously Short Introduction to the History of Medicine, Jaclyn Duffin warns us that the over-mechanization of the 19th
century risked the loss of insight into the mind-body connection.2
But increasingly the culture of medicine has been reaching back to
incorporate the subjective patient experience to include a spiritual, cultural, and psychological understanding of illness. In the 21st
century, perhaps a rigorous pursuit of knowledge will not cause us
to lose sight of the mind-body connection, but instead, enlighten us
with a greater appreciation for the body and the soul. This happy
marriage of objective science and subjective patient experiences
may be the aspect of modern medicine that allows for a deeper understanding of the mind-body connection, and ultimately, creates a
culture of medicine that reserves a space for the soul.
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A day with an orthoptist
Jeffrey Law (Meds 2016), Charles Yin (MD/PhD 2021)
Reviewer: Charla Snow, BSc, OC(C)

case presentation
The patient was only 6 years old but he had already been to
the hospital almost a dozen times. Today, as he was led to the
examination room, he clung tightly to his mother’s side. When
asked to take a seat in the examination chair, he began to cry.
Although he had been to the hospital more often than most kids
his age, he clearly didn’t find the setting enjoyable and he didn’t
want to be separated from his mother.
The patient had mild exotropia (outward deviation of the
eyes) from an early age. While he had never explicitly complained
of vision problems, he had a history of squinting frequently and
turning his head in an attempt to see more clearly. His mother,
on several occasions, had further suspected him of “seeing double”. On examination, the patient was diagnosed with amblyopia
and strabismus, and placed under the care of Charla, an orthoptist at St. Joseph’s Hospital, London.
On this occasion, the patient was very distraught by being in
the examination room. Charla was reluctant to have him take a
seat because he obviously wanted to be with his mother. Luckily,
Charla had a number of toys she kept in the office that she was
able to take out and have the patient play with to distract him.
The clinical exam comprised of a cover test for type of ocular deviation, horizontal and vertical prism bars to measure the
size of strabismus, Worth’s four light test for assessing degree
of binocular vision and suppression and having the patient go
through an image book and choose the image that looked “3D” in
order to assess binocular vision.
Over the course of the 30-minute appointment, a drastic
change overcame the demeanor of the patient. He had transformed from being quite distressed to more comfortable and
actually seemed to enjoy the various “games” that made up
his exam. The patient and his parents left the office with instructions to patch the unaffected eye in order to strengthen
the muscles in the weaker eye and restore proper vision and
alignment.

discussion
The 6-year-old boy with amblyopia and strabismus was one of
many patients I saw with an orthoptist during an observership in
the ophthalmology clinic at St. Joseph’s Hospital. Prior to my observership, I had never even heard of the profession. Luckily, I got
to spend the day with Charla Snow, a practicing orthoptist at St.
Joseph’s.
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Orthoptists are allied health professionals who specialize in
the study of eye movements, eye alignment and binocular vision.1
Orthoptists work closely with ophthalmologists in managing disorders such as amblyopia and strabismus. While ophthalmologists
formulate and implement surgical interventions, orthoptists provide primary care in the assessment, diagnosis and non-surgical
treatment of optical complaints.1
Strabismus is a condition in which the eyes are not properly
aligned. It is caused by an inherently misaligned eye or by a lack of
coordination between the extraocular muscles, preventing the eyes
from being able to focus on the same point in space.2 Symptoms include diplopia, eyestrain and loss of depth perception.2 In young
patients such as the 6-year-old from the case presentation, strabismus is particularly worrisome because of the risk of developing
amblyopia, a condition in which the brain compensates for the lack
of ocular alignment by suppressing vision in one eye.3 The result
is a form of cortical blindness where connections between the eye
and the brain do not develop properly and the brain consequently
ignores the images coming from that eye.3 In the management of
strabismus and amblyopia, orthoptists use a combination of glasses,
occlusion (patching) and prism therapy.1 Orthoptists also monitor
and reinforce the treatment plan by meeting with the patients on a
regular basis and offer support and guidance to the patient and his
or her family.1
Orthoptists work with a patient population that ranges from
infants just a few months old to seniors, but the majority of their
practice deals with children. As such, orthoptists have special skills
that facilitate working with this age range.1 In general, children
have shorter attention spans and are more difficult to examine than
adults.4 As such, orthoptists use a variety of tests designed to work
within the brief window of a child’s attention span. For example, in
order to check extraocular eye movements, Charla would have the
children track a toy with their eyes. The tests are also customized
for various age groups: the younger children were given the simpler task of naming shapes, while the older children were given the
more complex task of naming letters.
During my day at the clinic, I learned that orthoptics training
is at least two years in length following an undergraduate degree,
and often includes a third thesis year for the completion of a master’s degree.5 The curriculum involves learning the unique anatomy,
physiology and clinical skills required to excel in such a specialized
career. Just like medical schools, orthoptics programs in Canada
are accredited by the Canadian Medical Association and all trainees must write a 3-part national examination set by the Canadian
Orthoptic Council.5

Page 23

interdisciplinary
When we had a break between patients, I asked Charla where
orthoptists fit into the larger scheme amongst optometrists, ophthalmologists and general practitioners. I was told that her practice
has a very specialized scope of practice and orthoptists are able to
specialize in studying ocular motility and visual development.1 Although orthoptists cannot perform surgeries and require an ophthalmologist to work with them, having an orthoptist involved in
patient care means the management and treatment can be monitored more closely, enhancing the quality of patient care and overall
sense of patient satisfaction.6,7

conclusion
Towards the end of the day, I asked whether Charla ever ran
into conflicts with other members of the ophthalmology team. She
told me that having the ophthalmology clinic centralized at one hospital makes them a tight-knit group and contributes towards a high
level of interprofessional collegiality. Although there are occasionally differing opinions on the final diagnosis or different thoughts
about how a patient should be managed, Charla emphasized the
importance of trusting the skills that each specialty brings to the
table. Spending the day in clinic with Charla really brought home
to me that, regardless of what medical specialty I end up choosing,
developing a trusting and respectful relationship with allied health
professionals and working together effectively would be critical to
providing the best patient care possible.
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Optogenetics
Illuminating the brain
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Faculty Reviewer: Dr Susanne Schmid, PhD (Department of Anatomy and Cell Biology)

abstract
The nature of the brain presents many challenges to its
study, from the intricacy of its structure to the minute timescale at which it functions. Traditional research techniques,
such as electrophysiological manipulation and pharmacologic
intervention, are limited by their inability to operate with both
high temporal and spatial resolution. Optogenetics is a novel
technology that provides unparalleled specificity in this regard. It allows for control of neural activity with high temporospatial resolution in a manner that does not disrupt the normal
physiology of the system. It is an elegant research tool that uses
light to control the electrical activity of genetically defined
neuron populations with millisecond precision in systems as
complex as freely moving live animals. First demonstrated in
2005, it was identified by Nature as the Scientific Method of the
Year in 2010 and is currently used by thousands of labs across
the world. It has already yielded new discoveries in a variety
of neuroscience subfields and will undoubtedly continue to do
so. The technology currently exists in a basic science capacity,
but has potential for therapeutic application. It is not without
its own limitations, but has advantages over more crude alternatives and has proven to be a powerful tool in the hand of the
neuroscientist.

introduction
The human brain is the most intricate organ in the body and
has been referred to as “the most complex object in the known universe.”1 A recent estimate put the number of neurons in the human
brain at 86 billion2 with each neuron forming hundreds, if not thousands, of individual connections through which they communicate
on the millisecond scale. The complexity of its structure and function is astounding. For neuroscientists, this makes the brain both
irresistibly fascinating and prohibitively difficult to study. In order
to overcome the challenges that result from the inherent complexity of the brain, investigators must be creative and innovative in their
approach to its examination. The recent development of a research
tool known as optogenetics provides an ideal example of such innovation.

background
Traditional methods of study, such as with electrophysiological devices or pharmacologic intervention, have provided countless
insights into how the brain operates. However, each technique has
limitations. Direct electrical stimulation of tissue has high temporal
UWOMJ 84:1 | Winter 2015

resolution, but indiscriminately affects all cells around the microelectrode and thus has poor spatial resolution.3–5 Given that specifically targeted neurons are often sparsely embedded within tissue,
this is a significant drawback. Pharmacologic intervention on the
other hand has high spatial resolution, as drugs can be designed to
act on only certain neuron populations, but because the drug can
stay in the system for anywhere from minutes to hours such an approach lacks temporal resolution.4,5 Given the minute timescale at
which the brain operates, this is also a significant hindrance.
The idea of using light as a medium to control the activity of
neurons is not novel. It was speculated on by Francis Crick as far
back as 1979,6 however it was only first demonstrated in 2005.7,8
Since then, the lab of Karl Deisseroth at Stanford University has
published extensively on the topic9–17 and optogenetics has spread
to thousands of labs across the world.18 It is an elegant technique
that uses light to control the activity of genetically engineered neurons and has significant advantages over its more crude alternatives. Its significance has been recognized throughout the scientific
world, notably with Nature naming it Scientific Method of the Year
in 2010 and its early developers being honored as recipients of The
Brain Prize by the Grete Lundbeck European Brain Research Foundation in 2013.

details
Optogenetics, quite literally, refers to the convergence of optics
and genetics. When applied to neuroscience, it is a technology that
uses light to control the electrical activity of neurons with both high
temporal and spatial resolution in a manner that minimally disrupts
the normal physiology of the system. Thus, it overcomes some of
the limitations associated with traditional research techniques as
described above.
In order to achieve this, single-component, microbial-derived,
light-activated ion channel proteins called opsins are artificially
expressed in the membranes of neurons. This is predominantly accomplished through the use of viral vectors carrying specially designed genetic constructs, but can also be achieved using transgenic
animals.19 Regional specificity when using viral vectors can be ensured via the use of specific promoters, by localized viral injection,
and by restriction of opsin activity via targeted light delivery.4,20 The
family of proteins in play, opsins, was first discovered as a component of bacterial cell membranes over 40 years ago.21 Since then,
further research has enlarged the family and proteins have even
been altered in the laboratory to be more suitable for optogenetics research purposes.22 There currently exist dozens of opsin types
with unique characteristics, thus allowing for a variety of experimental configurations.22
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The genetic engineering techniques employed ensure that
the opsins are expressed exclusively in genetically defined target
population(s) of neurons and thus provide spatial resolution to the
cell-type level.23 Light is delivered via surgically implanted fiber
optics9–11 or other means.7,20,24 Upon exposure, the opsins alter their
conformation such that the flow of ions in or out of the neuron of
which they are a part is altered.22 Depending on both the type of
opsin involved and the wavelength of light used, the target cell(s)
are either depolarized (excited) or hyperpolarized (inhibited).22
This use of light as the metaphorical on/off switch for neuron activity provides the high temporal resolution. The light source can
be pulsed with enough speed and precision so as to reliably elicit
single spikes in neuron electrical activity.8 Furthermore, light is an
ideal medium to use for this purpose as it does not affect unaltered
neurons (neurons without opsins) and thus minimally disrupts normal brain physiology.8

recent research
Before discussing relevant current research, it is important to
note that optogenetics currently plays a role in basic science research exclusively. That is, its goal is not directly therapeutic, but
to give neuroscientists the ability to more closely examine the brain
and thus better understand how it functions. It is used in models of
both health and disease with the hope that the knowledge gained
will lead to the development of future therapies.
Optogenetics has been applied to nearly every area of neuroscience research18 and in models ranging from ex vivo cell lines8
to nonhuman primates.20 A sample of notable work using murine
models includes controlling behavior in freely moving animals,15
increasing functional recovery after stroke,10 mapping of Parkinsonian neural circuitry,12 inhibiting symptoms in a model of Parkinson’s,11 eliminating cocaine seeking behavior after addiction,16,25 and
inducing REM sleep.26 Last year researchers used optogenetics to
control in vivo transcription of endogenous genes in the brain, as
opposed to electrical neural activity.27
These represent some of the most dramatic recent advances in
optogenetics, but there are countless examples of labs applying this
technology to less complex in vitro systems. In vitro application of
optogenetics, such as in vitro slice electrophysiology, benefits from
the same principles that allow for exciting research in in vivo models, but is significantly less expensive (a few thousand dollars will
provide for a good start).28

future directions
Although optogenetics has come a long way since its debut a
decade ago, it remains in its infancy. There is enormous ongoing
research into its refinement and further development with exciting papers being published almost monthly.29 One intriguing topic
is the development of optical systems capable of the simultaneous
control and recording of neural activity. This is not possible to perform with electrophysiological devices and is just beginning to be
performed using optogenetic systems. It would provide unprecedented information about the organization and function of intact
neural networks.18,20,23
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The use of optogenetics as therapy for human disease is a natural direction to look in when considering the future of this technology. This, for reasons discussed below, is a distant, but not impossible, prospect. Based on current research, it could be applied in
various forms to assist in treating disease states including Parkinson’s,11,12 addiction,16,25 stroke recovery,10 epilepsy,17,30 and a variety of
neuropsychiatric diseases.4,31,32

limitations
As with any new technology, the limitations of optogenetics are
slowly appearing. Relating to basic science use, the pattern of ion
concentration changes induced by opsins does not perfectly replicate the actions potentials observed in normal physiology.29 The
conductance tends to be smaller33 and the magnitude of the ion concentration changes risks exceeding physiologic ranges.18 Exposure
of multiple opsin-containing neurons to light means their resulting
activity is synchronized and, given the precise timing of neural networks, potentially results in nonphysiologic patterns of activity.18
Furthermore, although light has desirable properties the heat created by its use poses a significant risk of damaging delicate tissue and
is something researchers must be cognizant of.28 These limitations,
among many others, threaten the validity of conclusions drawn
solely from the interpretation of optogenetic results.
Besides the onerous task of compiling the knowledge of neural function and dysfunction required to even hypothesize about
the use of optogenetics in the treatment of human disease, a major
limitation to this application is the dependence on genetic manipulation. Proving the long-term safety of gene therapy in humans to
the satisfaction of regulatory bodies is an immense undertaking.18,34
Combined with additional objectives, such as refining the methods
of light delivery in intact living tissue and demonstrating therapeutic effects beyond the scope of other methods, an enormous deal of
work needs to be completed before therapeutic application of optogenetics can be considered.5

summary
Optogenetics is a novel and sophisticated research tool.
Through the convergence of genetics, optics, and neurobiology it
allows for the control of neural activity with unparalleled temporospatial resolution in systems as complex as freely moving live animals. It is an elegant technique with significant advantages over
more crude alternatives and has provided us with new insights into
how the brain functions. With continued application and refinement it will continue to do so. It is currently applied only in terms
of basic science research, but has potential for a therapeutic role in
a variety of diseases.
Given its intriguing core principle (controlling the brain with
light), optogenetics is a topic prone to sensationalization and one
needs to keep in mind that significant limitations exist at both the
basic science and potential therapeutic levels.
In closing, I paraphrase the cautious champion of optogenetics, Karl Deisseroth, who said that optogenetics, although exciting,
should be viewed as only one tool among the many available to a
neuroscientist.32 Nevertheless, considering the task at hand, it is
one that I would want in my kit.
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In the first of three interviews in this issue, we speak to
Dr Javeed Sukhera. Dr Sukhera is an Assistant Professor in the
Department of Psychiatry and Senior Designate Physician Lead
for Child and Adolescent Psychiatry at London Health Sciences
Centre/Victoria Hospital. He is also the Academic Director of the
Global Health Curriculum at Schulich. Dr Sukhera has previously
served for two years on the board of directors of the Association of
American Medical Colleges.
UWOMJ: Tell us about yourself, specifically your education and
career.
Javeed Sukhera: I am originally from Toronto and did my undergraduate training there. I took the opportunity to study medicine
in Israel, which is where I was able to further explore my interests
in global health. I studied at the Medical School for International
Health, an innovative collaboration between Columbia University
and Ben-Gurion University in Israel. During my fourth year, I returned to Canada for an elective in adolescent psychiatry and that
is what sparked my interest in psychiatry. Prior to the elective, I was
was close to pursuing family medicine, but inevitably chose psychiatry. I then completed my residency in Rochester, New York, as well
as my fellowship. Two years ago, I decided to return to Canada, and
I came to London, Ontario.
What made you interested in pediatric psychiatry? What makes
this field unique?
I think that psychiatry is very unique because it is so different
from every other field in medicine. All throughout medical school,
you are taught to think a certain way. In psychiatry, you have to unlearn the need to always try to find a solution or a cure. There is
not always a medication or a quick fix within psychiatry, and often,
there is the opportunity for different methods of patient management. Pediatric psychiatry is especially interesting because you are
working with a population during a developmentally sensitive period that can have a long-lasting impact on the patient’s life.
Tell us about your other academic or personal interests and how
you balance that.
Between clinic, research and academic teaching responsibilities, I would roughly estimate that 40 percent of my time is clinical, 40 academic and 20 research. I was recently awarded a grant to
conduct research on unconscious biases within medicine and how
they affect patient outcomes. Due to my appointment, I also have
several academic responsibilities. For example, I am the Academic
Director of Global Health Curriculum at Schulich. At the Office of
Global Health, we have worked hard to integrate global health and
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public health topics into all four years of the undergraduate curriculum. Specific examples include the cultural competence workshop in your Population Health course and a Health Equity Panel in
the Healthcare Systems course.
Global health is something that is very important to me and is
an important part of my career. The old version of global health involved going abroad and providing healthcare in countries outside
of Canada. Over time, we have recognized the problem of medical tourism, but also recognize that there is a benefit to learning
medicine in different cultural environments. More recently, global
health is more about the patients sitting in front of us, especially in
Canada, and how understanding local and global contexts helps us
understand the social and cultural determinants affecting this specific patient’s care. Many students struggle with the idea of global
health in a local setting, but the same principles relating to cultural
competency apply both locally and globally.
How would you compare psychiatry to neurology or neurosurgery? What are the similarities or differences that you see? Do
you often work in interdisciplinary teams?
I would say that neurology is somewhere between psychiatry
and neurosurgery. We definitely work with neurology on certain
cases. The problems that we see are often biosocial in nature, and
there are referrals that flow in both directions. I would think of
neurology as a field that deals with the brain whereas psychiatry
is a field that deals with the mind. It is on rare occasions that we
might work with the neurosurgeons. More often than not, we might
be consulted by neurosurgery. The main difference for psychiatry
that makes it unique from other specialties is that psychiatric complaints are multifaceted and very complex. Just this morning, I saw
a boy with attention deficit hyperactivity disorder (ADHD)—a very
bright boy. Early on, he had acknowledged how he might have been
different and he has done well working with me. Our conversation
was not limited to his medication, but also the social aspects of his
illness. When someone has ADHD, it affects many parts of his life,
such as his education and friends, just as some examples. My treatment extended beyond offering medication and included providing
the opportunity to openly speak about the challenges of being a
teenager who may need to rely on medication while trying to fit in
with his peers.
Tell us about your family, or hobbies you have outside of work.
I am very lucky to have two beautiful children with my wife.
We all enjoy travelling, but my favourite hobby would probably be
just doing nothing on a Sunday afternoon.
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Do you have a memorable case to share?
There are just so many cases that are memorable. This one case
that I remember is actually from when I was a fourth-year medical
student. The patient was an adolescent male who adhered to Orthodox Jewish practices. He had very specific requests for his psychiatric care. For example, he refused to be touched by the female
nurse. At the time, my supervisor was actually also a rabbi, and he
was able to communicate genuinely with the patient. His approach
showed a lot of patience and understanding. In the end, the solution
that was finally agreed upon was for the patient to receive care from
the nurse, who would be able to touch him with gloves on.
What do you see as the challenges/innovations within psychiatry in the next 20 years?
I think a current challenge is the bias within medicine that a
lot of my patients face. You would be surprised at some of the comments that I hear from other physicians that stigmatize patients
with psychiatric illness. The treatment that a lot of psychiatric patients receive is simply unfair and stems from ignorance. Especially
in emergency rooms, these patients often face a lot of discrimination.
With psychiatry, there is also a great need to advocate for my
patients. There are essential and vital medications or treatments
that are not available everywhere. For example, some of my patients
from more rural locations do not have access to a psychiatrist near
them. Can you imagine that for other illnesses? For a diabetic not to
have access to insulin or a heart failure patient to not be able to be
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pay for ACE inhibitors? It would be unheard of! Within psychiatry,
there is a lot more for us to advocate for. This is a real challenge that
I unfortunately see in my practice. Moving forward, there is a lot of
room for improvement.
I see a lot of changes upcoming in psychiatry, especially with
new psychotherapies, and psychopharmacological treatments that
are being researched. So, there are some positive things to look forward to as well.
What are your thoughts about the new Diagnostic and Statistical
Manual of Mental Disorders (DSM) V?
I am not a huge fan of the DSMs because I find that their categorizations oversimplify the problems that we are presented with.
The DSM is helpful for providing guidelines for diagnosis, but most
of our patients do not fit neatly into the categories that the DSM
provides. I prefer to address the person in front of me instead of
treating a formulaic diagnosis provided by the DSM.
If a medical student is interested in psychiatry, do you have any
advice for them?
I would just say that there are many different facets to psychiatry. Pediatric psychiatry, for example, is very different. There is a
lot to experience and see in psychiatry. Use the clerkship psychiatry
rotation to explore and be open minded. You may be surprised at
what interests you and what field you can imagine yourself practicing in.
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Conversations with a neurologist
Interview with Dr Christen Shoesmith

Han Yan (Meds 2017), Ramona Neferu (Meds 2018)
Faculty Reviewer: Dr Christen Shoesmith, MD, FRCPC (Department of Clinical Neurological Sciences)

In the second of three interviews in this issue, we speak to
Dr Christen Shoesmith. Dr Shoesmith is a neurologist and the director of the Motor Neuron Diseases Clinic at the London Health
Sciences Centre (LHSC). She runs the local clinical research trials
in amyotrophic lateral sclerosis (ALS) and also sits on the ALS Canada Scientific Medical Advisory Panel. She is also heavily involved
in medical education at the undergraduate, residency, and fellowship levels. She is an Assistant Professor of Neurology at Western
University.
UWOMJ: Tell us a bit about yourself, specifically your education, career, and personal interests.
Christen Shoesmith: After studying medicine at the University of Manitoba, I completed my neurology residency and fellowship
here in London. I was fortunate enough to stay on staff after fellowship and have been a staff neurologist at LHSC since 2007.
I subspecialize in ALS and am the clinical director at the Motor
Neuron Diseases clinic at University Hospital. I also have a particular interest in patients who have neurological symptoms during
pregnancy.
Aside from my career, I love spending time with my husband
and my two beautiful daughters who are 7 and 5 years old, and I
enjoy jogging and yoga.
Why did you choose neurology?
I came into medical school with an interest in neurology, but
was open to other potential specialties, which I explored through
observerships. My undergraduate degree was in chemistry and
mathematics, so the analytical and algorithmic approaches to neurological problems were very stimulating for me. I also loved the
diverse patient population and the thrill of the diagnosis. In neurology, we see patients in their 20s through their 90s with a variety
of neurological disorders. In my first two years of medical school, I
attended weekly neurology teaching rounds at the adjoining hospital, and had great mentors who helped me grow in my knowledge
and exposure to neurology in medical school.
When I started my neurology residency here at Western, I
loved everything about the field, but it became clear early on that
I had an interest in palliative care. Initially I explored neuro-oncology but I didn’t feel it involved sufficient intellectual challenge
for me, since the diagnosis is already there when the patient comes
into your care. In contrast, working in the field of neuromuscular
disease and ALS gave me the thrill of localization and diagnosis,
so it was a natural fit. I also had the complete fortune of having
Dr Michael Strong as my mentor in my residency and fellowship. He
was instrumental in guiding me through my early career opportunities.
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Thoughts on ALS ice bucket challenge?
In the ALS community, everyone is absolutely thrilled that the
ice bucket challenge happened. Patients spread awareness about the
disease they’re living with, and the community has a much broader
understanding of how ALS can affect individuals and families.
Some people in the lay media have spoken out against the ice
bucket challenge saying that the funds should have been divided
more equitably amongst other diseases initiatives. However, ALS
rarely has its face in the spotlight or gets large sums of funding, unlike cancer or heart and stroke.
The other negative publicity issue is that people have looked at
the financial statements of ALS Canada and assumed that the distribution of the new funds would be made in the same percentages
as previously. However the cost of running the organization won’t
change substantially, so this one-time donation can be diverted directly to patient support services and research.
Is there a memorable case you would like to share?
The cases that I remember most are the ones where I have
made the right diagnosis that other clinicians may have missed. It is
rewarding to know that you’ve spent the time and energy to make a
correct diagnosis. The cases where I have made mistakes or where
I did not use the best clinical judgment are also memorable, as well
as those cases with complex ethical issues. Some patients have displaced their anger on me about their diagnosis of ALS. I’ve learned
to appreciate that patients have different reactions to diagnoses,
and a negative reaction doesn’t necessarily mean that you’ve provided bad care to the patient.
What can you do as a neurologist to make sure that you catch the
diagnoses others have missed?
It is very important in neurology to take a great history: let the
patient tell their story and not put words into their mouth. Listening
to all facets of the story is really important so you can hear about the
progression of their symptoms over time. Next, unlike a lot of other
areas of medicine, a meticulous physical examination in neurology
is still extremely important and it is vital to arriving at a correct diagnosis. To put together a diagnosis, it’s important to take the time
to think about what all the findings mean. You also can’t be afraid to
revisit a diagnosis, whether it is your own or someone else’s.
The field of neurology is still perceived by many to be a field of
diagnosis rather than curing. What are your thoughts on this issue?
From an outsider’s perspective, there is the perception that
neurology is a “diagnose and adios” profession. But neurology has
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absolutely changed—it’s a very different field than when I was a
medical student. When I started as a medical student, there were
very few treatments available for multiple sclerosis (MS). Now,
we’ve got multiple drugs that have substantially improved the
course of MS. Inflammatory conditions, stroke, epilepsy, and seizures have also seen tremendous improvements in management.
There are, of course, neurologic disorders that we can’t treat
yet, but there are huge amounts of research being done and I certainly think that in my lifetime, diseases like ALS will have better
treatments. I never tell my patients we can’t do anything about their
diagnosis. I explain that we can help manage symptoms with pharmacological management and we also direct people to appropriate
allied health professionals. For example, getting an ankle foot orthotic for someone that has foot drop, or getting the appropriate
therapist to help with dysphagia can make a huge difference in a
patient’s quality of life.
How much do you interact with neurosurgeons or psychiatrists?
In London we have a Clinical Neurological Sciences department, so neurosurgeons and neurologists are part of the same faculty, sharing the same resources and physical space. At our site, there
is likely more academic interaction between neurology and neurosurgery than at centres where the two specialties are under separate departments (medicine and surgery). This model allows for a
shared type of care where we can learn from each other.

From a career perspective, what are the job options and opportunities for neurologists when they finish residency?
Unlike neurosurgery where underemployment is an issue, neurology doesn’t have that problem. There are certainly many urban
centres and smaller centres like Thunder Bay and Sudbury that are
looking for more neurologists. The majority of the positions are not
in academic institutions at the moment, but soon many neurologists will be retiring. As well, because the baby boomer population
is getting older and neurological disorders are more prevalent with
increasing age, there will be an increased need for neurologists over
time.
If students are interested in neurology, what should they do to
further explore the field?
For students who are interested in neurology, it’s worth getting
perspectives from different types of practices and many neurologists through observerships and electives. Medical students can also
attend Clinical Neurological Sciences grand rounds, as well as neurology lunchtime rounds. The schedule for weekly rounds is available online on the Clinical Neurological Sciences website. Research
is sometimes a bonus when applying for neurology residencies, but
not necessary. From a preceptor’s point of view, the students that
are eager to learn in a clinical setting and have a basic knowledge of
neurology/neuroanatomy are the ones that are teachable and a good
fit for the program.

Where do you see neurology going in the next 20 years or so?
There will be more treatments for genetic conditions in neurology. A lot of research is being done but right now there aren’t
specific treatments for most genetic disorders in neurology. As well,
we’ll be moving more towards more personalized medicine where
different genetic factors will predict different treatments for neurological disorders.
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Conversations with a neurosurgeon
Interview with Dr Fawaz Siddiqi

Han Yan (Meds 2017), Ramona Neferu (Meds 2018)
Faculty Reviewer: Dr Fawaz Siddiqi, MD, MBA, FRCSC, FACS (Department of Clinical Neurological Sciences)

In the third of three interviews in this issue, we speak to Dr
Fawaz Siddiqi. Dr Siddiqi is an Assistant Professor of Neurosurgery
and Orthopaedics at Western University. He is the president of the
Professional Service Organization and sits on the Medical Advisory
Committee as well as the London Health Sciences Centre Board of
Directors. He is also the course chair for the Healthcare Systems
course at the Schulich School of Medicine and Dentistry.
UWOMJ: Tell us a bit about yourself, your career path and your
education path.
Fawaz Siddiqi: I did my undergraduate degree in biochemistry
at the University of Ottawa and came to Western for medical school.
I did my neurosurgery residency training and an orthopaedic spine
fellowship here, after which I came on as faculty. Clinically, I’m one
of four spine surgeons in our combined neurosurgery and orthopaedic spine program at Victoria Hospital in London. My practice
encompasses degenerative spinal conditions, oncology, and trauma.
What made you interested in neurosurgery? What makes it
unique?
My attraction to neurosurgery happened relatively early in my
career. I spent my summers after first and second year of medical
school with the neurosurgical service at a hospital back home in
Ottawa. Spending time with the neurosurgical team helped me determine whether it was something I wanted to do.
Neurosurgery is a challenging field to work in and it attracts
people who really crave that sort of challenge. The procedures and
patient population are very diverse. Neurosurgeons perform many
procedures to help people with a variety of conditions. Neurosurgeons help with chronic pain through spinal cord stimulation, with
movement disorders such as Parkinsonism through the use of deep
brain stimulation, and curing epilepsy with surgical resections. In
addition, we deal with oncological conditions of the brain and spine
as well as vascular conditions, such as cerebral aneurysms and vascular malformations.
Spinal surgery itself is very rewarding. Patients come in who
have a lot of difficulty walking and they can walk again after the operation. That’s not something that a lot of specialties can lay claim to.
How would you compare neurology, psychiatry, and neurosurgery?
While the pathologies may overlap, the objectives and practice
patterns of the practitioners are very different. That said, there is
a huge amount of crossover between neurosurgery and neurology
in terms of pain management, treatment for movement disorders,
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and epilepsy. Surgeons who work in those fields usually work in
interdisciplinary teams. Epilepsy is a perfect example. You can’t
be an effective epilepsy surgeon if you don’t have an effective epilepsy neurology partner. The same is true with movement disorder
work. The bulk of my collaboration with other physicians is with
oncologists and neurologists. As for psychiatry, there are more and
more data suggesting that stimulation of certain areas of the brain,
namely the areas of the limbic system and the cingulate gyrus, can
actually help with depression as well.
Can you tell us a little bit about your Master of Business Administration (MBA) or other academic or personal interests you
have?
During training, neurosurgical residents usually get a research/
elective period of about 9 months. Most people will use that to do
a master’s degree of some sort or a research project or an elective.
When I looked at the breadth of options available to me, the MBA
seemed to be the most effective degree in looking at healthcare
systems operationally and being able to work through some of the
problems that we have such as delivery of care to our patients.
For a physician who is involved in management, it can be a very
powerful tool to have in your back pocket. I encourage people to
look into it as a professional career option as the healthcare system
evolves and encounters new difficulties, whether it be a funding
perspective or from a structural perspective. We are going to need
more and more physician voices involved in these issues.
One of the current projects that I am involved with at an institutional level is collaborating on working towards achieving better
physician participation in healthcare management. Since the bulk
of healthcare costs actually are driven by the physician’s pen, physicians need to be more engaged in healthcare institution management in order to achieve efficient healthcare delivery. Traditionally,
physicians worked as islands in most hospitals and clinics with very
little oversight or participation in attempting to make the system
better. This archaic model has to change.
What do you think the challenges are in neurosurgery in the next
twenty years?
The outcomes from primary brain tumour treatment haven’t
changed much in the last number of years, and the prognosis remains pretty dismal for some types of brain tumours (12-14 months
median survival with maximal therapy for primary high-grade glioma). So, from a research and innovation perspective, the causative
factors of primary brain tumours still remains elusive.
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The other challenge is really delivery of care. The wait list for
a spinal surgery can often times reach two years for consultation,
and an additional year for surgery. The way we deliver consultative
services to patients has to change. We can’t rely on the traditional model where you have a physiotherapist, chiropractor, or family
physician refer to a surgeon in isolation. We really need an interdisciplinary model of care for this specific patient population that will
shorten wait times and improve evidence-based care.
What’s new and exciting in your field of neurosurgery?
We are achieving a much better understanding of spinal biomechanics and becoming better at treating spinal diseases, whether minimally invasively or with open surgery. There is increasing
awareness of the role of neurosurgery for epilepsy surgery, as well
as for Parkinsonism, movement disorders, and chronic pain conditions.
Do you have any comments about future job prospects in neurosurgery in Canada and elsewhere?
We have not had enough jobs in Canada to sustain the number
graduating from neurosurgery, so many neurosurgeons found jobs
in the United States after training. Most centres in the US are still
hiring Canadian-trained neurosurgeons and recognizing the Canadian training. In my year, we had three of us stay in Canada and
everyone else went to the US, and as far as I know, everyone is employed and has fantastic jobs.

How is the balance between family time, call-time, and day-today work?
All twelve members in our faculty are married, and most of us
have children. I think achieving a work-life balance is very manageable. The Victoria Hospital neurosurgeons have a call frequency of
1 in 4 and we do call a week at a time, but I usually go home around
6:30 pm, and am back for meetings around 7:00 am. In general, I’m
not up every single night operating, and we have a good vacation
roster. Gone are the days where people are living in the hospitals
and not seeing their families.
If a medical student is interested in neurosurgery, what advice
would you have for them?
The best thing to do is really explore the specialty through clinical electives and spend time with the neurosurgical service. That
will give you the best perspective as to what the practice looks like
and the pathology that you will be dealing with on a regular basis.
It’s harder if you haven’t had that experience to look at it as a viable specialty option because you really haven’t experienced what
it’s like and you have only an abstract concept of what a neurosurgeon might do. But that’s really advice that I give for anybody who
is looking at any specialty.

Are there opportunities for working abroad for medical relief
purposes?
Organizations tend to recruit pediatric neurosurgeons due to
the high burden spina bifida and hydrocephalus in these nations.
There is a role for surgeons in medical education abroad through
entities such as the American College of Surgeons.
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When the beat clots

Ischemic stroke in atrial fibrillation
Kevin Braden (Meds 2017), Nicole Arseneau (Meds 2018)
Faculty Reviewer: Dr Allan Skanes, MD, FRCPC (Division of Cardiology)

An emergency room physician is asked to see a 68-year-old
male complaining of mild chest discomfort, intermittent palpitations, and worsening shortness of breath. The patient presented to
the emergency room with an acute onset of palpitations and states
a 3-month history of fatigue. At triage, blood pressure is 135/90
mmHg, respiratory rate is 16 breaths per minute, and an irregular
heart rate at 125 bpm at rest is identified. Additionally, his history is
notable for a 30-pack-year smoking history and longstanding, reasonably controlled hypertension. On further evaluation, the patient
develops increasing confusion and light-headedness.
A 12-lead electrocardiogram (ECG) demonstrates the absence
of discrete P waves and an irregularly irregular ventricular rate, diagnostic of atrial fibrillation. However, immediately following the
identification of atrial fibrillation on ECG, the patient begins describing a weakness in his left hand. His symptoms progress over
the next ten minutes until he can no longer lift his arm and has trouble speaking. Concerned, the emergency physician immediately begins assessment of ischemic stroke.

thrombogeneisis in atrial fibrillation
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia
characterized by uncoordinated atrial activation and subsequent
diminution of mechanical function.1 Rapid, ectopic firing of multiple atrial foci, resulting in the asynchronous depolarization of the
atria, produces the characteristic cardiac arrhythmia. Due to the
rapid and chaotic atrial activity, AF leads to disorganized mechanical atrial function, irregular ventricular rate, and hemodynamic
irregularities, ultimately generating a prothrombotic environment.2
The most serious complication of atrial fibrillation is a thromboembolic event, such as an ischemic stroke, which can lead to
permanent neurological damage. An ischemic stroke may occur in
patients with AF either as the primary presenting manifestation of
AF or in patients with previously diagnosed AF despite appropriate medical management. In such patients, a cardiac embolus most
frequently originating from the left atrium is thought to be a main
source of ischemic strokes in patients with AF.3

initial assessment of ischemic stroke in atrial
fibrillation
Atrial fibrillation is the most common cardiac arrhythmia seen
in clinical practice and is an important contributor to increased
morbidity and mortality, largely due to thromboembolic events
such as ischemic stroke.4,5 As a result of an acute embolic obstruction to cerebral circulation, an ischemic stroke manifests with the
abrupt onset of focal neurologic deficits, with symptoms of stroke
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remaining indefinitely if irreversible neurological damage occurs
as a result of the cerebral ischemia. As such, prompt assessment
and management is key when stroke is strongly suspected. Following the assessment of vital signs and ensuring the stabilization of
airway, breathing, and circulation, a focused history and physical
examination should be promptly obtained.6
The single most influential item with regards to patient history
in stroke evaluation is the time of symptom onset, defined as the
last known time when the patient was at their previous baseline
or symptom-free state.1 Determining the time of ischemic stroke
symptom onset is of crucial importance, and acts a main determinant of eligibility for acute intravenous thrombolysis treatment. For
patients unable to provide this information at the time of presentation, consulting patient family members, bystanders, or emergency
medical service personnel may be required. After identifying time
of symptom onset, a thorough history and physical exam should
follow, focusing on identifying the progression of symptoms, possible embolic sources, and any concomitant patient comorbidities
that may impact management of an ischemic stroke. Any contraindications to thrombolytic treatment should also be assessed at this
time.6
An initial neurological examination should be promptly performed following physical examination. Formal stroke evaluations,
as guided by documents such as the National Institutes of Health
Stroke Scale (NIHSS), have demonstrated clinical utility as a form
of rapid neurological assessment, and may be administered successfully by a broad spectrum of healthcare providers.7,8 The three most
predictive examination findings for the diagnosis of acute stroke
are facial paresis, abnormal speech, and arm drift/weakness.9,10
Blood should be drawn to evaluate complete blood count, platelet
count, blood glucose, electrolytes, cardiac markers, and coagulation
studies. Furthermore, timely brain imaging remains critical to the
rapid evaluation and diagnosis of patients with potential ischemic
strokes. Imaging may be used to exclude the presence of intracranial hemorrhage, assess the degree of brain injury, and identify the
vascular lesion responsible for the ischemic deficit. Either computed tomography or magnetic resonance imaging may be used as the
initial imaging modality for the emergent assessment of patients
with suspected stroke.6
The emergency physician, quickly recognizing the signs of
stroke and noting the onset of stroke symptoms, immediately begins
the clinical stroke evaluation using the NIHSS. Blood is drawn, immediately sent to the laboratory, and imaging studies are arranged.
An urgent consult to the stroke service is made and decisions for
early management are considered.
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acute management of ischemic stroke
Following the diagnosis of ischemic stroke, timely restoration
of cerebral blood flow using fibrinolytic therapy is the most effective pharmacological maneuver for salvaging viable ischemic brain
tissue.11 As previously mentioned, the single most influential item
with regards to patient history is the time of symptom onset, in
order to aid in determining the eligibility for acute intravenous fibrinolytic treatment. Additionally, any contraindications to intravenous thrombolysis must also be strictly evaluated.6
For eligible patients with acute ischemic stroke, intravenous
fibrinolytic therapy in the form of intravenous recombinant tissue-type plasminogen activator (rtPA) alteplase is currently the
widely accepted approach.12,13 Timely thrombolytic therapy administered within the therapeutic window, recognized as within 4.5
hours from symptom onset, has demonstrated significant reductions of long-term disability with no increase in long-term mortality.14,15 Most importantly, earlier treatment is more likely to result in favorable outcomes, further emphasizing the importance of
timely emergency department evaluation and diagnosis of ischemic
stroke.16
Intracranial hemorrhage remains the major risk of intravenous
rtPA treatment, with early neurological symptoms associated with
intracranial hemorrhage occurring in 6.4% of patients treated with
intravenous rtPA.17 Thus, strong emphasis must be placed on initial
assessment and patient history to ensure appropriate selection of
patients for intravenous fibrinolysis.
For patients ineligible for intravenous rtPA, a number of endovascular treatment options have become available including intra-arterial fibrinolysis, mechanical clot aspiration or retrieval, and
acute angioplasty with stenting. Although these therapies may offer
favourable outcomes, these alternative therapies should be pursued
only in a highly selected patient population ineligible for intravenous rtPA and in centres well equipped for these modalities.1
Returning to the case, the initial investigations and imaging results return and demonstrate early signs of cerebral infarction and
identify the site of thromboembolism. Additionally, the imaging
results exclude any signs of intracranial hemorrhage. Without any
contraindications to fibrinolytic therapy, and presenting within the
narrow therapeutic window, the patient is started on intravenous
rtPA and monitored closely for the next 24 hours.

long-term prevention of thromboembolism in atrial
fibrillation
Long-term management of patients with AF often involves
three considerations: rate control, rhythm control, and prevention
of thromboembolism. Initially, the AF management decision involves the determination between either a rate or rhythm control
strategy; however, regardless of which strategy is pursued, attention must also be directed to antithrombotic therapy for prevention
of thromboembolism.18
Multiple clinical strategies have been proposed to stratify the
risk of ischemic stroke in patients with AF to determine which
patients might benefit from antithrombotic therapy. A currently
accepted stratification scheme, the CHADS2, integrates elements
UWOMJ 84:1 | Winter 2015

from several strategies and identifies patients which will benefit from antithrombotic therapy. The CHADS2 scoring system is
a point-based system in which 2 points are assigned for a history
of stroke or transient ischemic attack, and 1 point each is assigned
for the presence of cardiac failure, hypertension, diabetes, and age
over 75 years.19 In patients with AF and a CHADS2 score ≥1, longterm oral anticoagulation with warfarin or a new anticoagulant,
such as apixaban, dabigatran, or rivaroxaban, unless contraindicated, is recommended. Patients with a CHADS2 score of 0, if over 65
years, still benefit from long-term oral anticoagulation, while patients with AF and no additional risk factors need no therapy.18 Antithrombotic therapy has been shown to successfully lower the risk
of embolization in all patients with AF, however its use is associated
with an increased risk of bleeding and requires monitoring for risk
of bleeding complications.20,21
Due to the rapid response and recognition of the signs of ischemic stroke by the emergency physician, the patient suffered only
minimal neurological sequelae. During the recovery from his ischemic stroke, the patient is educated on his arrhythmia and metoprolol is initiated to achieve rate control. Anticoagulation is also initiated to reduce the risk of further stroke—his CHADS2 score is 3.
He is followed up by a cardiologist to review the management of his
atrial fibrillation and risk for recurrent stroke. Further discussions
are made to ensure proper maintenance of his hypertension and
discuss future considerations for smoking cessation.
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Maggots on the brain (and in it)
A case of cerebral myiasis
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introduction
In the aftermath of a traffic collision, it can be common for
emergency responders to find the victims disoriented, confused,
or even aggravated. Often, this is the result of the psychological or
physical trauma sustained during the collision.1 On occasion, any
number of prior medical conditions may be contributing to a victim’s altered mental status. These may even be the primary cause
for their presentation, complicating the situation for both the initial responders and emergency room medical staff.2 Our case begins
in just such a fashion. After a low-velocity collision, a 75-year-old
Californian man was found behaving erratically and aggressively
by emergency responders. Responders diligently removed the patient’s hat to check for injuries. Under the hat was not an injury
related to blunt trauma sustained during the collision, as one might
expect, but rather a lesion with exposed cerebral matter which contained a clear infestation by maggots. The patient was subsequently
brought to the emergency room for further investigation.3
While simple lesions of the scalp are often benign, resulting
from minor trauma or common dermatological conditions, lesions
which perforate the skin, bone, and meninges such as the one seen
in our case are quite rare.4 Penetrating head injuries, neoplastic conditions and severe cranial infections are the most likely suspects.3,5,6
In the case of penetrating head injuries, gunshot wounds, stabbings,
and motor vehicle collisions are the most prevalent.5 Possible neoplastic conditions include osteoma or osteosarcoma of the cranial
bones, hemangioma, and angiosarcoma.3,6,7 Potential cranial infections include brain abscesses due to bacterial or fungal infections.8

case presentation & diagnosis
Investigation continued at the hospital with a patient history provided by family members. The lesion had started as a reddish-purple nodule on the frontal scalp. Over the course of a year,
it had expanded, ulcerated, and ultimately become infested with
maggots. Although various family members had advised treatment
for the nodule, the patient had refused, citing religious reasons. The
patient resided with his wife, who had been diagnosed with advanced Alzheimer’s, and his contact with the rest of his family was
infrequent. Additionally, later investigations revealed extremely
poor living conditions, exemplified by garbage accumulation, animal fecal matter, and the presence of rodents. These factors allowed
the lesion erosion and subsequent infestation to develop undetected until the collision.3
On physical examination, the patient displayed obvious poor
hygiene and presented with a strong putrid odour. The patient’s
vital signs and temperature were unremarkable. The cranial lesion was examined in detail. It presented with substantial erosion,
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measuring 15 cm x 17 cm, and extended bilaterally over the frontal
cranial region from the orbital rim to the parietal scalp. Within the
lesion the dura was absent, exposing cerebral brain tissue. Two cortical defects were found around the midline of the lesion, each of
which contained dense clusters of live maggots embedded within
the brain tissue. A count of the number of live maggots was deemed
impractical and not performed. The maggots engaged in active
movement in all regions of the defect, including the surface of the
exposed cerebral tissue.3
The patient remained conscious but torpid, and responded to
simple commands. Further neurological examination was normal.
A complete blood count and white blood cell differential was performed, revealing a WBC count of 20 100/mm3, 91% neutrophils
and no bands. Blood culture in the emergency room indicated the
presence of penicillin-sensitive group G Streptococcus.3
Finally, a computerized tomography scan identified multiple
skeletal and abdominal lesions, including a destructive soft tissue
mass in the left posterior chest wall. This mass was centered at the
T9 vertebral body and extended into the spinal canal. Needle biopsies of the lesion sites revealed poorly differentiated spindle-shaped
CD31-, CD34-positive cells. Additionally, the patient had swollen
parotid glands, which also tested positive for the same cell types.
These finding supported a diagnosis of metastatic angiosarcoma.3

management
The patient was admitted to intensive care. Broad-spectrum
antibiotics were started, specifically a regimen of intravenous vancomycin, ceftriaxone, and metronidazole. Maggot extraction was
moderately successful, and was performed via gentle suction. The
remaining maggots were covered with sterile surgical dressings
soaked in a mild bleach solution. No living maggots remained after
3 days.3
Psychiatric evaluation determined the patient competent to
make his own medical decisions. The patient declined any surgery
and any treatments for his metastatic angiosarcoma. The family as
well as the ethics committee upheld his decision. Because he declined surgery, the cortex remained exposed following treatment,
until his death 3 months later following his transfer to a nursing
facility.3

discussion
Cerebral myiasis is an exceedingly rare condition, with only a
handful of described cases worldwide. The vast majority of these
cases have been identified postoperatively. All reported cases which
state an outcome have unfortunately resulted in death of the patient, although the cerebral myiasis may not have been a main conPage 37
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tributor to their deaths. In this case, the more immediate threat was
likely the presence of group G β-hemolytic Streptococcus, which can
present indistinguishably from a group A streptococcal infection,
while the ultimate cause of death was presumably due to the untreated metastatic angiosarcoma.3,9 Indeed, without the open cranial lesion caused by the angiosarcoma, the maggot infestation would
have likely been self-limiting; the short lifecycle of the fly species
discovered (Phaenicia sericata, commonly called the green bottle
fly) would have resulted in the elimination of live maggots within
a week or so without continuous deposition of new eggs by adult
flies.3,10
With the exception of the case presented here, all have occurred outside North America. Reported cases of cerebral myiasis
indicated lesions which were less extensive than the one seen in
this case. The presence of angiosarcoma as the primary cranial lesion could have contributed to the extent of the infestation. Maggots of the common green bottle fly preferentially feed on dead tissue, and have been used in maggot therapy to debride away dead
tissue. In this case, tumor growth may have continuously provided
necrotic material to sustain the maggots.3,10,11
As there have been so few cases of cerebral myiasis, no standard treatment exists. Removal of the maggot infestation, as was
conducted in this case, would seem to be an appropriate course
of action. Broad spectrum antibiotics to treat concurrent bacterial
infections and ward off secondary infection would also appear to
be prudent, particularly as the presence of Phaenicia sericata larvae may help protect against bacterial infections, a protection that
may be removed with the elimination of the infesting maggots.3,11
Evaluation of mental status should be undertaken to determine the
extent of cognitive impairment, if any, and to establish competence
to direct care.3
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conclusion
This is an extremely unlikely case of cerebral myiasis that has
invaded through the meninges. That this case was identified only
after evaluation after a low-speed collision, and that cognitive function was still largely intact is truly remarkable given the extent of
the infestation. In medicine, we are told that when we hear hoof
beats, we should think horses, not zebras, and certainly not fictional unicorns. This first reported case of cerebral myiasis in North
America with its highly improbable presentation is about as close
to a unicorn as we come in modern medicine.
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